Methods of identifying insect-TRPA1 modulators

ABSTRACT

The invention provides a screening method for identifying an insect-specific TRPA1 modulator by comparing modulation of an insect TRPA1 and a mammalian TRPA1. The invention further provides method of insect control by applying to an insect a insect-specific TRPA1 modulator identified by the screening method.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. §371 National Stage Entry Application ofInternational Application No. PCT/US2011/028853, filed Mar. 17, 2011,which designates the U.S., and which claims benefit under 35 U.S.C.§119(e) of the U.S. Provisional Application No. 61/314,905, filed Mar.17, 2010, the content of which is incorporated herein by reference inits entirety.

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Aug. 12, 2015, isnamed 047364-067622-US_SL.txt and is 213,270 bytes in size.

GOVERNMENT SUPPORT

This invention was made with government support under R21 MH080206, R01MH067284 and PO1 NS044232 awarded by the National Institutes of Health.The Government has certain rights in the invention.

BACKGROUND OF INVENTION

Insects cause great losses and damages to human agriculture, foodsupply, post-harvest storage, horticulture, animal health and publichealth. While advances have been made in the control of these insects,these insects have been able to adapt and evade the control measures.

Animals from flies to humans are equipped with biological sensors forsensing the environment and its changes, and help dictate the behavioralresponse to the environmental changes. Accordingly, there remains a needfor methods identifying compounds that are species specific modulatorsof biological sensors.

SUMMARY OF THE INVENTION

In one aspect the invention provides a method of identifyinginsect-specific TRPA1 modulator comprising: (a) contacting a testcompound with an insect TRPA1 and a mammalian TRPA1; and (b) assayingmodulation of insect and mammalian TRPA1 activity.

In another aspect the invention provides a method of insect controlcomprising modulating chemo- and/or thermo-sensing in an insect with acompound identified by the methods described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1D show that dTrpA1 mediates gustatory responses to reactiveelectrophiles. Chemical structures of allyl isothiocyanate (AITC),N-methyl-maleimide (NMM) and cinnamaldehyde (CA) (FIG. 1A). Proboscisextension response (PER) frequency at five sequential tastant offerings,ingestion permitted, for wild type (-●-) and dTrpA1^(ins) (-▪-) (FIG.1B); *p<0.05, **p<0.01, unpaired t-test). PER frequency when tastantcontacts only legs (FIG. 1C). Five sequential offerings combined (n≧10flies). PER frequency when ingestion permitted (FIG. 1D). In FIG. 1D,for each TrpA1 allel: upper bar (light), first offering; lower bar(dark), second to fifth offerings combined. Statistically distinctgroups marked by different letters (Tukey HSD, α=0.01). Data aremean+/−SEM. All studies use 12% (350 mM) sucrose, alone or with 100 mMcaffeine, 2 mM AITC, 10 mM NMM, or 6 mM CA. n=3 groups of ≧7 flies,unless noted.

FIGS. 2A-2C are bar graph showing dTrpA1 functions in chemosensors. PERto 350 mM sucrose containing 10 mM NMM for dTRPA1 knockdown (FIG. 2A),dTRPA1 rescue (FIG. 2B), and dTRPA1 gain-of-function (FIG. 2C).Ingestion permitted (FIGS. 2A and 2B, n=3 groups of 7-8 flies) or tarsalcontact only (FIG. 2C, n≧10 flies). (*: α=0.05, **: α=0.01, differ fromGal4 and UAS controls, Tukey HSD). In FIGS. 2A and 2B, for eachconstruct: upper bar (light), first offering; lower bar (dark), secondto fifth offerings combined.

FIGS. 3A-3G show that insect TRPA1s are reactive electrophile sensors.Representative responses of dTRPA1 (FIGS. 3A-3D) and agTRPA1 (FIG. 3E)expressed in oocytes. Left panels, currents at −60 and +60 mV. Perfusionbuffer containing indicated chemical at 100 μM (FIGS. 3A, 3C and 3D) or40 μM (FIGS. 3B and 3E) was applied for 60-80 sec. 100 μM ruthenium red(RR) applied as noted. Right panels show I-V relationships at pointsmarked on left panels. FIGS. 3F and 3G show ectopic dTRPA1 expressionconfers electrophile sensitivity upon motor neurons. Motor neuron-drivenexcitatory junction potentials (EJPs) from third instar larval muscles(FIG. 3F) and mean EJP frequencies (FIG. 3G). In controls, no EJPs wereobserved.

FIG. 4A shows response of TRPA1-wt (wild type) and dTRPA1-2C channels inXenopus oocytes. 60 sec pulses of AITC (0.1, 0.5, and 1.0 mM) wereapplied with 25 sec intervals. FIG. 4B depicts a bar graph showing +60mV currents normalized to channel's response to 1.0 mM AITC. *p<0.05,**p<0.001, unpaired t-test.

FIG. 5 depicts bar graph showing painless mutant responses to reactiveelectrophiles. PER responses, ingestion permitted. Upper bar (lightblue), PER for first offering; lower bar (dark blue), PER for second tofifth offerings combined. AITC and NMM significantly inhibited PERresponses in painless mutant flies, although the inhibitory effect wasless than in wild type. Statistically distinct groups marked bydifferent letters (Tukey HSD, α=0.05 for +AITC, α=0.01 for +NMM). n=3groups of 7-8 flies. For each construct: upper bar (light), firstoffering; lower bar (dark), second to fifth offerings combined.

FIGS. 6A-6D show dose-response and dTRPA1-dependence of chemicallyactivated currents in oocytes. AITC dose-response curves for dTRPA1orthologs from D. melanogaster, D. mojavensis and D. virilis (FIG. 6A).Uninjected oocytes did not respond to reactive electrophiles whentreated with 3 mM AITC (FIG. 6B), 1 mM CA (FIG. 6C) and 0.1 mM NMM (FIG.6D). In FIGS. 6A-6C, +60 mV (∘) and −60 mV (●).

FIGS. 7A and 7B show that thermal and chemical activation of dTRPA1yield currents with similar I-V properties. Warmth-activated dTRPA1currents (left panel) and their I-V relationships (right panel) (FIG.7A) and AITC-activated dTRPA1 currents (left panel) and their I-Vrelationships (right panel) (FIG. 7B). In both cases, the degree ofoutward rectification of the channel decreases as dTRPA1 is increasinglyactivated. Also note that while heat-activated currents decline rapidlyupon cooling (FIG. 7A), chemically activated currents are more sustained(FIG. 7B), consistent with covalent modification of the channel by AITC.

FIG. 8 shows that ectopic Painless expression does not confer pungentchemical sensitivity upon motor neurons. Intracellular recordings fromthird instar larval muscles of OK371>Painless animals before and duringtreatment with 500 μM cinnamaldehyde (CA). CA application does notinduce excitatory junctional potentials (EJPs).

FIGS. 9A and 9B show that warming robustly activates dTRPA1-2C.Representative warmth-evoked currents in oocytes expressing wild type(dTRPA1 wt) and mutant (dTRPA1-2C) TRPA1 channels. Peak amplitude ofwarmth-evoked currents (FIG. 9B). Differences in peak amplitude did notreach statistical significance.

FIGS. 10A and 10B show that dTRPA1 did not detectably respond to 2-APBor nicotine. dTRPA1 expressing oocytes did not respond to treatment with100 μM 2-APB (FIG. 10A) or nicotine (FIG. 10B). Subsequent activation ofdTRPA1 by heat (FIG. 10A) and/or the cysteine-modifying reagentphenylarsine oxide (PAO, 30 μM) (FIG. 10B) was used to confirm that theoocytes expressed functional dTRPA1 channels.

DETAILED DESCRIPTION OF THE INVENTION

TRPA1 is a non-selective cation channel belonging to the larger familyof TRP ion channels. The TRP channels constitute a large and importantclass of channels involved in modulating cellular homeostasis. TRPchannels have been classified into at least six groups: TRPC (short),TRPV (vanilloid), TRPM (long, melastatin), TRPP (polycystins), TRPML(mucolipins), and TRPA (ANKTM1). The TRPC group can be divided into 4subfamilies (TRPC1, TRPC4,5, TRPC3,6,7 and TRPC2) based on sequencehomology and functional similarities. Currently the TRPV family has 6members. TRP V5 and TRP V6 are more closely related to each other thanto TRPV1, TRP V2, TRPV3, or TRPV4. TRPA1 is most closely related toTRPV3, and is more closely related to TRPV1 and TRPV2 than to TRPV5 andTRPV6. The TRPM family has 8 members. Constituents include thefollowing: the founding member TRPM1 (Melastatin or LTRPC1), TRPM3(KIAA1 616 or LTRPC3), TRPM7 (TRP-PLIK, ChaK(1), LTRPC7), TRPM6 (ChaK2),TRPM2 (TRPC7 or LTRPC2), TRPM8 (Trp-p8 or CMR1), TRPM5 (Mtr1 or LTRPC5),and TRPM4 (F1120041 or LTRPC4). The sole mammalian member of the TRPAfamily is ANKTM1. The TRPML family consists of the mucolipins, whichinclude TRPML1 (mucolipins 1), TRPML2 (mucolipins 2), and TRPML3(mucolipin3). The TRPP family consists of two groups of channels: thosepredicted to have six transmembrane domains and those that have 11.TRPP2 (PKD2), TRPP3 (PKD2L1), TRPP5 (PKD2L2) are all predicted to havesix transmembrane domains. TRPP1 (PKD13 PC1)5 PKD-REJ and PKD-IL1 areall thought to have 11 transmembrane domains. The TRPA1 is expressed ina great number or organisms: mammals (humans, mice, rats, monkeys andchimpanzee), zebrafish, insects (Drosophila, Tribolium, Pediculus,Culex, Anopheles), and red jungle fowl to name a few.

The inventors have discovered that the Transient Receptor Potential ionchannel A1 (TRPA1) exhibits species specific differences in response todifferent chemical compounds. Accordingly, in one aspect the inventionprovides a method of identifying an insect-specific TRPA1 modulatorcomprising: (a) contacting a test compound with an insect TRPA1 and amammalian TRPA1; (b) assaying activation of the insect and mammalianTRPA1.

In some embodiments, the method further comprises the step of comparingthe activation of the insect TRPA1 with the mammalian TRPA1.

In some embodiments, the method also comprises the step of selecting thecompound which preferentially modulates the insect TRPA1 relative to themammalian TRPA1.

Activation of TRPA1 can be assayed using conventional in vitro and invivo methods well known to the skilled artisan, such as thetwo-electrode voltage clamping on Xenopus lavis oocytes or EJP frequencymeasuring in larval neuromuscular junctions as described herein. Othermethods of assaying TRPA1 activation include those described in Hinman,et al., Proc. Natil. Acad. Sci. USA, 103: 19564-19568 (2006);Macpherson, et al., Nature, 445: 541-445 (2007); Hamada, et al., Nature,454: 217-220 (2008); Xiao, et al., J. Neurosci. 28: 9640-9651 (2008);Talvara, Talavera, et al., Nature Neurosci. 12, 1293-1299 (2009); andInt. Pat. App. No. PCT/US09/46933, filed Jun. 10, 2009, content of allof which is herein incorporated by reference. For example, the channelactivity of TRPA1 can be assayed using a variety of assays to measurechanges in ion fluxes including patch clamp techniques, measurement ofwhole cell currents, radiolabeled ion flux assays, and fluorescenceassays using voltage-sensitive dyes (see, e.g., Vestergarrd-Bogind etal., J. Membrane Biol. 88:67-75 (1988); Daniel et al., J. Pharmacol.Meth. 25:185-193 (1991); Hoevinsky et al., J. Membrane Biol. 137:59-70(1994)). For example, a nucleic acid encoding a TRPA1 protein or homologthereof can be injected into Xenopus oocytes. Channel activity can thenbe assessed by measuring changes in membrane polarization, i.e., changesin membrane potential. One means to obtain electrophysiologicalmeasurements is by measuring currents using patch clamp techniques,e.g., the “cell-attached” mode, the “inside-out” mode, and the “wholecell” mode (see, e.g., Ackerman et al., New Engl. J. Med. 336:1575-1595,1997). Whole cell currents can be determined using standard methodologysuch as that described by Hamil et al., PFlugers. Archiv. 391:185(1981).

Channel activity is also conveniently assessed by measuring changes inintracellular Ca²⁺ levels. Such methods are well known in the art. Forexample, calcium flux can be measured by assessment of the uptake ofCa²⁺ or by using fluorescent dyes such as Fura-2. In a typicalmicrofluorimetry assay, a dye such as Fura-2, which undergoes a changein fluorescence upon binding a single Ca²⁺ ion, is loaded into thecytosol of TRPM8-expressing cells. Upon exposure to a test compound, anincrease in cytosolic calcium is reflected by a change in fluorescenceof Fura-2 that occurs when calcium is bound.

The activity of TRPA1 can be also assessed using a variety of other invitro and in vivo assays to determine functional, chemical, and physicaleffects, e.g., measuring the binding of TRPA1 to other molecules,including peptides, small organic molecules, and lipids; measuring TRPA1protein and/or RNA levels, or measuring other aspects of TRPA1polypeptides, e.g., transcription levels, or physiological changes. Whenthe functional consequences are determined using intact cells oranimals, one can also measure a variety of effects such as changes incell growth or pH changes or changes in intracellular second messengerssuch as IP3, cGMP, or cAMP, or components or regulators of thephospholipase C signaling pathway.

Generally, a compound can be tested at any concentration that canmodulate the activity of insect TRPA1 over an appropriate time period.In some embodiments, the compound is tested at a concentration in therange of about 0.1 nM to about 1000 mM. Preferably the compound istested in the range of about 100 μM to about 1000 μM. In onenon-limiting example, the compound is tested at 0.05 mM, 0.1 mM, 0.2 mM,0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1 mM, 1.1 mM,1.2 mM, 1.3 mM, 1.4 mM, 1.5 mM, 1.6 mM, 1.7 mM, 1.8 mM, 1.0 mM, or 2 mM.

In some embodiments, the compound is tested at two or more differentconcentrations. Preferably the highest concentration tested is at least2×, at least 3×, at least 4×, at least 5×, at least 6×, at least 7×, atleast 8×, at least 9×, at least 10×, at least 250×, at least 25×, atleast 50×, at least 75×, at least 100× higher than the lowestconcentration employed. For a non-limiting example, the compound istested at 0.1 mM, 0.5 mM, and 1 mM.

Generally, a compound can be contacted with insect and/or mammalianTRPA1 for any length of time before measuring and activity of saidTRPA1. For example, a compound can be contacted with insect and/ormammalian TRPA1 for at least 5 seconds, at least 10 seconds, at least 15seconds, at least 30 seconds, at least 45 seconds, at least 1 minute, atleast 2 minutes, at least 3 minutes, at least 4 minutes, at least 5minutes, at least 10 minutes, at least 15 minutes, at least 30 minutes,at least 60 minutes, or more before activity of TRPA1 is measured. Insome embodiments, activity is measured at the instant when the TRPA1 iscontacted with a compound.

In some embodiments, activity is measured over a period of time. Forexample, activity can be measured for a period of at least 5 seconds, atleast 10 seconds, at least 15 seconds, at least 30 seconds, at least 45seconds, at least 1 minute, at least 2 minutes, at least 3 minutes, atleast 4 minutes, at least 5 minutes, at least 10 minutes, at least 15minutes, at least 30 minutes, at least 60 minutes, or more. Themeasurement period can start at the instant when the TRPA1 is firstcontacted with a compound or start after a period of time after theTRPA1 is first contacted with a compound. The TRPA1 can be continuouslycontacted with the compound while activity is measured.

In some embodiments, the method further comprising the step of selectingthe test compound that preferentially modulates the insect TRPA1relative to a mammalian TRPA1. By preferential modulation is meant thatactivity of insect TRPA1 is modulated by at least 5%, at least 10%, atleast 20%, at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, at least 95%, at least 100%, ormore relative to the mammalian TRPA1.

In some embodiments, the test compound does not modulate the activity ofthe mammalian TRPA1, e.g., the tested compound has no significant effecton the mammalian TRPA1 activity.

In some embodiments, the test compound has an EC50 of less than or equalto 500 nM, less than or equal to 250 nM, less than or equal to 100 nM,less than or equal to 50 nM, less than or equal to 10 nM, less than orequal to 1 nM, less than or equal to 0.1 nM, less than or equal to 0.01nM, or less than or equal to 0.001 nM for activating an insect TRPA1.

In some embodiments, the compound has an IC50 of less than or equal to500 nM, less than or equal to 250 nM, less than or equal to 100 nM, lessthan or equal to 50 nM, less than or equal to 10 nM, less than or equalto 1 nM, less than or equal to 0.1 nM, less than or equal to 0.01 nM, orless than or equal to 0.001 nM for inhibiting an insect TRPA1.

Without wishing to be bound by theory, identification of selectivemodulators of insect TRPA1s can maximize pest deterrence whileminimizing irritation to other animals.

As used herein, the term “test compound” refers to the collection ofcompounds that are to be screened for their ability to specificallymodulate insect TRPA1 while having little effect on mammalian TRPA1s.The test compounds of the invention encompass numerous classes ofchemical molecules, e.g., small organic or inorganic molecules,polysaccharides, biological macromolecules, e.g., peptides, proteins,peptide analogs and derivatives, peptidomimetics, nucleic acids, nucleicacid analogs and derivatives, an extract made from biological materialssuch as bacteria, plants, fungi, or animal cells or tissues, naturallyoccurring or synthetic compositions. Generally, the test compounds canhave a molecular weight of about 50 to 500,000.

As used herein, the term “small molecule” can refer to compounds thatare “natural product-like,” however, the term “small molecule” is notlimited to “natural product-like” compounds. Rather, a small molecule istypically characterized in that it contains several carbon-carbon bonds,and has a molecular weight more than about 50, but less than about 5000Daltons (5 kD). Preferably the small molecule has a molecular weight ofless than 3 kD, still more preferably less than 2 kD, and mostpreferably less than 1 kD. In some cases it is preferred that a smallmolecule have a molecular mass equal to or less than 700 Daltons.

In some embodiments, the test compound is a synthetic molecule. Bysynthetic molecule is meant a molecule that does not occur in nature.

In some embodiment, the test compound is a naturally occurring molecule.Such a molecule can be used in a purified or unpurified form, i.e., asobtained from the biological source.

Depending upon the particular embodiment being practiced, the testcompounds may be provided free in solution, or may be attached to acarrier, or a solid support, e.g., beads. A number of suitable solidsupports may be employed for immobilization of the test compounds.Examples of suitable solid supports include agarose, cellulose, dextran(commercially available as, i.e., Sephadex, Sepharose) carboxymethylcellulose, polystyrene, polyethylene glycol (PEG), filter paper,nitrocellulose, ion exchange resins, plastic films,polyaminemethylvinylether maleic acid copolymer, glass beads, amino acidcopolymer, ethylene-maleic acid copolymer, nylon, silk, etc.Additionally, for the methods described herein, the test compounds maybe screened individually, or in groups. Group screening is particularlyuseful where hit rates for effective test compounds are expected to below such that one would not expect more than one positive result for agiven group.

The number of possible test compounds runs into millions. Methods fordeveloping small molecule, polymeric and genome based libraries aredescribed, for example, in Ding, et al. J Am. Chem. Soc. 124: 1594-1596(2002) and Lynn, et al., J. Am. Chem. Soc. 123: 8155-8156 (2001). Anumber of small molecule libraries are known in the art and commerciallyavailable. Commercially available compound libraries can be obtainedfrom, e.g., ArQule, Pharmacopia, graffinity, Panvera, Vitas-M Lab,Biomol International and Oxford. These libraries can be screened usingthe screening methods described herein. Chemical compound libraries suchas those from of 10,000 compounds and 86,000 compounds from NIH Roadmap,Molecular Libraries Screening Centers Network (MLSCN) can also be used.A chemical library or compound library is a collection of storedchemicals usually used ultimately in high-throughput screening orindustrial manufacture. The chemical library can consist in simple termsof a series of stored chemicals. Each chemical has associatedinformation stored in some kind of database with information such as thechemical structure, purity, quantity, and physiochemical characteristicsof the compound.

In some embodiments, the insect TRPA1 is in a biological cell. In someembodiments, the mammalian TRPA1 is in a biological cell. The term“biological cell” or “cell” as used herein has its commonly understoodmeaning. Inside a cell, the TRPA1 can be expressed from an endogenousgene in the cell or a from a vector that is transfected into the cell.The skilled artisan is well aware of methods and protocols fortransfecting cells with vectors for expressing proteins of interest.

The insect TRPA1 used in the screening assay can be any insect TRPA1 orhomolog thereof. In some embodiments, the insect TRPA1 is selected fromthe group consisting of D. melanogaster TRPA1 isoform F (Accession No.ABW08500.3) (SEQ ID NO: 1), D. melanogaster TRPA1 isoform E (AccessionNo. AAF50356.4) (SEQ ID NO: 2), D. melanogaster TRPA1 isoform F(Accession No. NP_001097554.3) (SEQ ID NO: 3), D. melanogaster TRPA1isoform E (Accession No. NP_648263.4) (SEQ ID NO: 4), D. melanogasterTRPA1 (Accession No. Q7Z020.3) (SEQ ID NO: 5), Anopheles gambiae TRPA1(Accession No. ACC86138.1) (SEQ ID NO: 6), Tribolium castaneumhypothetical protein TcasGA2_TC002449 (Accession No. EFA01253.1)(SEQ IDNO: 7), and conservative variants thereof.

The mammalian TRPA1 used in the screening assay can be any mammalianTRPA1 or homolog thereof. In some embodiments, the mammalian TRPA1 isselected from the group consisting of Rattus norvegicus transientreceptor potential cation channel, subfamily A, member 1 (Accession No.NP_997491.1) (SEQ ID NO: 8); Rattus norvegicus transient receptorpotential cation channel subfamily A member 1 (Accession No. AAS78661.1)(SEQ ID NO: 9); Mus musculus transient receptor potential cationchannel, subfamily A, member 1 (Accession No. NP_808449.1) (SEQ ID NO:10); Homo sapiens transient receptor potential cation channel subfamilyA member 1 (Accession No. NP_015628.2) (SEQ ID NO: 11); Mus musculustransient receptor potential cation channel, subfamily A, member 1(Accession No. AAI31964.1) (SEQ ID NO: 12); Mus musculus transientreceptor potential cation channel, subfamily A, member 1 (Accession No.AAI20564.1) (SEQ ID NO: 13); Mus musculus transient receptor potentialcation channel, subfamily A, member 1, isoform CRA_b (Accession No.EDL14332.1) (SEQ ID NO: 14); Mus musculus transient receptor potentialcation channel, subfamily A, member 1, isoform CRA_a (Accession No.EDL14331.1) (SEQ ID NO: 15); Bos Taurus transformation sensitive proteinp120 (Accession No. XP_581588.2) (SEQ ID NO: 16); Pan troglodytespredicted ankyrin-like protein 1 (Accession No. XP_519806.2) (SEQ ID NO:17); Macaca mulatta predicted ankyrin-like protein 1 (Accession No.XP_001083172.1) (SEQ ID NO: 18); Gallaus gallus predicted similar totransient receptor potential cation channel subfamily A member 1(Accession No. XP_418294.2) (SEQ ID NO: 19); Danio rerio TRPA1(Accession No. AAV37177.1) (SEQ ID NO: 20); Danio rerio transientreceptor potential cation channel, subfamily A, member 1a (Accession No.NP_001007066.1) (SEQ ID NO: 21), and conservative variants thereof.

As used herein, a “conservative variant” is an amino acid sequence inwhich a first amino acid is replaced by a second amino acid or aminoacid analog having at least one similar biochemical property, which canbe, for example, similar size, charge, hydrophobicity or hydrogenbonding capacity. For example, a first hydrophobic amino acid can beconservatively substituted with a second (non-identical) hydrophobicamino acid such as alanine, valine, leucine, or isoleucine, or an analogthereof. Similarly, a first basic amino acid can be conservativelysubstituted with a second (non-identical) basic amino acid such asarginine or lysine, or an analog thereof. In the same way, a firstacidic amino acid can be conservatively substituted with a second(non-identical) acidic amino acid such as aspartic acid or glutamicacid, or an analog thereof or an aromatic amino acid such asphenylalanine can be conservatively substituted with a second aromaticamino acid or amino acid analog, for example tyrosine. In someembodiments, the peptide comprises conservative variant substitution ofat least one amino acid, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or moreamino acids. Typically, a conservative variant will retain at least 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more ofthe activity of the wild-type peptide sequence.

Exemplary conservative variant substitution include, but are not limitedto, replacement of Alanine (A) with D-ala, Gly, Aib, β-Ala, Acp, L-Cys,or D-Cys; Arginine (R) with D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg,Met, Be, D-Met, or D-Ile; Asparagine (N) with D-Asn, Asp, D-Asp, Glu,D-Glu, Gln, or D-Gln; Aspartic acid (D) with D-Asp, D-Asn, Asn, Glu,D-Glu, Gln, or D-Gln; Cysteine (C) with D-Cys, S-Me-Cys, Met, D-Met,Thr, or D-Thr; Glutamine (Q) with D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, orD-Asp; Glutamic Acid (E) with D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, orD-Gln; Glycine (G) with Ala, D-Ala, Pro, D-Pro, Aib, β-Ala, aor Acp;Isoleucine (I) with D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, orD-Met; Leucine (L) with D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met,or D-Met; Lysine (K) with D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met,D-Met, Ile, D-Ile, Orn, or D-Orn; Methionine (M) with D-Met, S-Me-Cys,Be, D-Ile, Leu, D-Leu, Val, or D-Val; Phenylalanine (F) with D-Phe, Tyr,D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4 or 5-phenylproline,AdaA, AdaG, cis-3, 4 or 5-phenylproline, Bpa, or D-Bpa; Proline (P) withD-Pro, L-I-thioazolidine-4-carboxylic acid, or D- or-L-1-oxazolidine-4-carboxylic acid (U.S. Pat. No. 4,511,390); Serine (S)with D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met (O), D-Met (O), L-Cys,or D-Cys; Threonine (T) with D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met,Met (O), D-Met (O), Val, or D-Val; Tyrosine (Y) with D-Tyr, Phe, D-Phe,L-Dopa, His, or D-His; and Valine (V) with D-Val, Leu, D-Leu, Ile,D-Ile, Met, D-Met, AdaA, or AdaG.

Conservative variants of the TRPA1s can be prepared according to methodsfor altering peptide sequences known to one of ordinary skill in theart, and include those that are found in references which compile suchmethods, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, etal., eds., Second Edition, Cold Spring Harbor, or Current Protocols inMolecular Biology, F. M. Ausubel, et al., eds., John Wiley & Sons, Inc.New York. Conservative variants of TRPA1 can also be made by alterationof a nucleic acid encoding the TRPA1 polypeptide.

In some embodiments, the screening method is a high-throughputscreening. High-throughput screening (HTS) is a method for scientificexperimentation that uses robotics, data processing and controlsoftware, liquid handling devices, and sensitive detectors.High-Throughput Screening or HTS allows a researcher to quickly conductmillions of biochemical, genetic or pharmacological tests.High-Throughput Screening are well known to one skilled in the art, forexample, those described in U.S. Pat. Nos. 5,976,813; 6,472,144;6,692,856; 6,824,982; and 7,091,048, and contents of each of these areherein incorporated by reference in their entirety.

HTS uses automation to run a screen of an assay against a library ofcandidate compounds. An assay is a test for specific activity: usuallyinhibition or stimulation of a biochemical or biological mechanism.Typical HTS screening libraries or “decks” can contain from 100,000 tomore than 2,000,000 compounds.

The key labware or testing vessel of HTS is the microtiter plate: asmall container, usually disposable and made of plastic, that features agrid of small, open divots called wells. Modern microplates for HTSgenerally have either 384, 1536, or 3456 wells. These are all multiplesof 96, reflecting the original 96 well microplate with 8×12 9 mm spacedwells.

To prepare for an assay, the researcher fills each well of the platewith the appropriate reagents that he or she wishes to conduct theexperiment with. After some incubation time has passed to allow thereagent to absorb, bind to, or otherwise react (or fail to react) withthe compounds in the wells, measurements are taken across all theplate's wells, either manually or by a machine. Manual measurements areoften necessary when the researcher is using microscopy to (for example)seek changes that a computer could not easily determine by itself.Otherwise, a specialized automated analysis machine can run a number ofexperiments on the wells such as current or voltage measurements,colorimetric measurements, radioactivity counting, etc. In this case,the machine outputs the result of each experiment as a grid of numericvalues, with each number mapping to the value obtained from a singlewell. A high-capacity analysis machine can measure dozens of plates inthe space of a few minutes like this, generating thousands ofexperimental data points very quickly.

In another aspect, the invention provides a compound selected by thescreening assay described herein. It is to be understood that analogs,derivatives, isomers, and pharmaceutically acceptable salts of thecompounds selected by the screening assays described herein are alsoincluded herein.

The compound or group of compounds being selected by the methodaccording to the invention can be used in methods of insect control,e.g. by modulating an environment sensing mechanism, for examplemodulating thermo- and/or chemo-sensing, in an insect. The identifiedcompounds, analogs, derivatives, isomers, and pharmaceuticallyacceptable salts thereof are also referred to as active agents herein.While not wishing to be bound by theory, the modulation of TRPA1 elicitsa signaling pathway that brings forth motor neuron modulation which canincrease or decrease movement of an insect from a non-optimalenvironment. Accordingly, in one aspect the invention provides a methodof insect control by modulating thermo- and/or chemo-sensing in aninsect using a compound identified by the screening methods describedherein. As used in context of methods of insect control, compoundsidentified by the screening methods described herein also includeanalogs, derivatives, isomers and pharmaceutically acceptable salts ofsuch compounds.

In some embodiments, the compound modulates the thermo-sensing pathwayof the insect. As used herein, the term “thermo-sensing pathway” refersto a signaling pathway involved in setting the preferred temperature inan insect. Without wishing to be bound by theory, activation of thethermo-sensing pathway allows an insect or non-insect pest to move froma non-preferred temperature (hot or cold) to a preferred temperature.

In some embodiments, the compound modulates the chemo-sensing pathway ofsaid insect. As used herein, the term “chemo-sensing pathway” refers toa signaling pathway involved in making the insect or non-insect moveaway from or towards a compound present in the environment.

It is envisioned that the methods described herein are also applicableto pest control, wherein the pests are not insects but rather, e.g.,nematodes, slugs or snails.

Without wishing to be bound by theory, activation of TRPA1 ion gatedchannel or family members in the insect leads to an increase inavoidance behavior of such insect. This increase in avoidance behaviorcan be used to repel insects away from a particular location and thuscontrolling such insects. Thus, in some embodiments, the methodcomprises activation of TRPA1 ion channel or family members in theinsect with a compound identified by a screening method describedherein.

Because compounds incorporating hydrophobic moieties will penetrate theinsect cuticle, active agents can be conjugated with hydrophobicmoieties. Hydrophobic moieties include, but are not limited to, lipidsand sterols. These conjugated active agents can then be administeredtopically, such as by direct spraying on the insect or a substrate whichis likely to be contacted by the insect. Alternatively, the activeagents may also be administered either subcutaneously, percutaneously,or orally. When they are to be ingested, they should be applied withtheir carrier to the insect diet.

In one embodiment, the methods described herein are applicable toinsects that are disease vectors. Vectors are organisms that canintroduce a pathogen such as a bacterium or virus into a host organismto cause an infection or disease. Exemplary disease vector include, butare not limited to, mosquitoes, Ticks, Siphonaptera (fleas), Diptera(flies), Phthiraptera (lice) and Hemiptera (true bugs).

Rat fleas, especially Xenopsylla cheopis (the Oriental rat flea), arethe principle vectors of Pasturella pestis, the bacterial pathogen ofbubonic plague. Fleas can also transmit murine typhus caused byRickettsia mooseri.

Black flies spread Onchocerca volvulus, a parasitic roundworm.Onchoceriasis, the disease caused by infestation of these worms, maycause blindness in peoples of Africa, Mexico, and Central and SouthAmerica. Sand flies in the genus Phlebotomus are vectors of a bacterium(Bartonella bacilliformis) that causes Carrion's disease (oroyo fever)in South America. In parts of Asia and North Africa, they spread a viralagent that causes sand fly fever (pappataci fever) as well as protozoanpathogens (Leishmania spp.) that cause Leishmaniasis. Mosquitoes in thegenus Anopheles are the principle vectors of malaria, a disease causedby protozoa in the genus Trypanosoma. Aedes aegypti is the main vectorof the viruses that cause yellow fever and dengue. Other viruses, thecausal agents of various types of encephalitis, are also carried byAedes spp. mosquitoes. Wuchereria bancrofti and Brugia malayi, parasiticroundworms that cause filariasis, are usually spread by mosquitoes inthe genera Culex, Mansonia, and Anopheles. Horse flies and deer fliesmay transmit the bacterial pathogens of tularemia (Pasteurellatularensis) and anthrax (Bacillus anthracis), as well as a parasiticroundworm (Loa loa) that causes loiasis in tropical Africa. Eye gnats inthe genus Hippelates can carry the spirochaete pathogen that causes yaws(Treponema pertenue), and may also spread conjunctivitis (pinkeye).House flies (family Muscidae), blow flies (family Calliphoridae), andflesh flies (family Sarcophagidae) often live among filth and garbage.They can carry the pathogens for dysentary (Shigella dysentariae),typhoid fever (Eberthella typhosa), and cholera (Vibrio comma) on theirfeet and mouthparts. They have also been suspected as vectors of theviral agent that causes poliomyelitis. Tsetse flies in the genusGlossina transmit the protozoan pathogens that cause African sleepingsickness (Trypanosoma gambiense and T. rhodesiense).

Human lice (Pediculus humanus and P. capitus) spread Borelliarecurrentis, a spirochaete pathogen that causes epidemic relapsingfever. They also carry the rickettsial pathogens that cause epidemictyphus (Rickettsia prowazeki) and trench fever (R. quintana).

Assassin bugs (or kissing bugs) in the genera Triatoma and Rhodniustransmit a protozoan pathogen (Trypanosoma cruzi) that causes Chagasdisease in South and Central America. In another embodiment, the methodsdescribed herein are applicable to arachnids that are disease vectors,such as spiders or ticks. As used herein, the term insect may beextended to include other members of the phylum anthropoda that are notscientifically classified as members of the class insecta.

In one embodiment, the methods described herein are applicable toinsects that are agricultural or horticultural vectors or pest. Insects,mites, and nematode vectors focus the movement of plant pathogens amongimmobile plants. Many insects or other arthropods may contain plantpathogens but cannot transmit these to plants and thus are not vectors.Some of our most important plant diseases require mobile vectors. Almostall plant viruses and all wall-free, plant pathogenic bacteria known asmollicutes have recognized or suspected vectors. See elsewhere forinsect vector transmission of bacterial plant pathogens. Examples ofsome of such plant pathogen vectors are Agromyzidae, Anthomyiidae,Aphid, Brevicoryne brassicae, Curculionidae, Eumetopina flavipes,Frankliniella occidentalis, Jumping plant louse, Leaf beetle,Leafhopper, Mealybug, Molytinae, Pissodes-Pissodes strobe, Pissodini,Planthopper Pseudococcus viburni, Scirtothrips dorsalis, Tephritidae,Thripidae, Tomicus piniperda Treehopper, Whitefly, and Bactrocera andCeratitis species of fruit flies

In one embodiment, the methods described herein are applicable toinsects that are parasites. Examples of some insect parasites areBraconid Wasps, family Braconidae; Ichneumonid Wasps, familyIchneumonidae; Chalcid Wasps, family Chalcidae; Tachinid Flies, familyTachonidae.

The active ingredient, or formulations comprising them, may be applieddirectly to the target insects (i.e., larvae, pupae and/or adults), orto the locus of the insects. In one embodiment, the active ingredient ora formulation containing the active ingredient is applied directly tothe adult insect. In one embodiment, the active agent is applieddirectly to the larvae and/or pupae of the target insect. In anotherembodiment, the active ingredient is applied to the locus of theinsects.

In another embodiment, after application of active ingredient, heat isapplied to the target insects or to the locus of the insects.

In one embodiment, the active ingredient is applied as a spray. Forexample, the active ingredient is applied as an agricultural spray inaerial crop dusting, an environmental spray to control biting insects,or as a topical spray for localized control of biting insects. Theactive ingredient is formulated for the purpose for spray applicationsuch as an aerosol formulation. Spray application can be accomplishedwith a spray pump. The active ingredient can be also encapsulationwithin materials such as starch, flour and gluten in granularformulations.

In one embodiment, the active ingredient is applied topically, forexample, as a lotion, a cream, or as a spray.

In one embodiment, the active ingredient is applied in conjunction withother insecticides and/or pesticides such as organo-phosphates,synthetic pyrethroids, carbamates, chlorinated hydrocarbons, when usedin agricultural and/or environmental insect control.

In another embodiment, for topical application, the active ingredient isapplied in conjunction with other compounds such as insect repellentsand sunscreen. Insect repellents include, but are not limited to, DEET(N,N-diethyl-m-toluamide), essential oil of the lemon eucalyptus and itsactive ingredient p-menthane-3,8-diol (PMD), icaridin (also known aspicaridin, Bayrepel, and KBR 3023), nepetalactone, also known as “catnipoil”, citronella oil, permethrin, soybean oil, neem oil and Bog Myrtle,Sunscreens include, but are not limited to, oxybenzone, titanium dioxideand zinc oxide.

The active ingredient is administered in an amount effective to inducethe desired response as determined by routine testing. The actualeffective amount will of course vary with the specific activeingredient, the target insect and its stage of development, theapplication technique, the desired effect, and the duration of theeffect, and may be readily determined by the practitioner skilled in theart. An effective amount of active ingredient is the amount of activeingredient to modulate activation of TRPA1, e.g., themosensing and/orchemosensing in an insect.

Formulation and Application

Methods of formulation are well known to one skilled in the art and arealso found in Knowles, D A (1998) Chemistry and technology ofagricultural formulations. Kluwer Academic, London, which is herebyincorporated by reference in its entirety. One skilled in the art will,of course, recognize that the formulation and mode of application mayaffect the activity of the active ingredient in a given application.Thus, for agricultural and/or horticultural use the TRPA1 inhibitorsand/or agonists may be formulated as a granular of relatively largeparticle size (for example, 8/16 or 4/8 US Mesh), as water-soluble orwater-dispersible granules, as powdery dusts, as wettable powders, asemulsifiable concentrates, as aqueous emulsions, as solutions, assuspension concentrate, as capsule suspensions, as soluble (liquid)concentrates, as soluble powders, or as any of other known types ofagriculturally-useful formulations, depending on the desired mode ofapplication. It is to be understood that the amounts specified in thisspecification are intended to be approximate only, as if the word“about” were placed in front of the amounts specified.

These formulations may be applied either as water-diluted sprays, ordusts, or granules in the areas in which insect control is desired.These formulations may contain as little as 0.1%, 0.2% or 0.5% to asmuch as 95% or more by weight of active ingredient, e.g. TRPA1inhibitor.

Dusts are free flowing admixtures of the active ingredient with finelydivided solids such as talc, natural clays, kieselguhr, flours such aswalnut shell and cottonseed flours, and other organic and inorganicsolids which act as dispersants and carriers for the toxicant; thesefinely divided solids have an average particle size of less than about50 microns. A typical dust formulation useful herein is one containing90 parts, 80 parts, 70 parts, 60 parts, 50 parts, 40 parts, 30 parts, 20parts, preferably 10 parts, or less of the active ingredient, e.g. TRPA1inhibitor or TRPA1 agonist. In one embodiment, the dust formulationcomprises 1 part or less of the active ingredient and 99 parts or moreof talc. As used herein, the terms “active ingredient” and “activeagent” refer to a compound that modulate the activity of TRPA1 ion gatedchannel or family member. By the term “modulate” is meant either toinhibit TRPA1 or activate TRPA1.

Wettable powders, useful as formulations, are in the form of finelydivided particles that disperse readily in water or other dispersant.The wettable powder is ultimately applied to the locus where insectcontrol is needed either as a dry dust or as an emulsion in water orother liquid. Typical carriers for wettable powders include Fuller'searth, kaolin clays, silicas, and other highly absorbent, readily wetinorganic diluents. Wettable powders normally are prepared to containabout 5-80% of active ingredient, depending on the absorbency of thecarrier, and usually also contain a small amount of a wetting,dispersing or emulsifying agent to facilitate dispersion. For example, auseful wettable powder formulation contains 80.0 parts of the activeingredient, 17.9 parts of Palmetto clay, and 1.0 part of sodiumlignosulfonate and 0.3 part of sulfonated aliphatic polyester as wettingagents. Additional wetting agent and/or oil will frequently be added toa tank mix for to facilitate dispersion on the foliage of the plant.

Other useful formulations are emulsifiable concentrates (ECs) which arehomogeneous liquid compositions dispersible in water or otherdispersant, and may consist entirely of the active ingredient, and aliquid or solid emulsifying agent, or may also contain a liquid carrier,such as xylene, heavy aromatic naphthas, isophorone, or othernon-volatile organic solvents. For insecticidal application theseconcentrates are dispersed in water or other liquid carrier and normallyapplied as a spray to the area to be treated. The percentage by weightof the essential active ingredient may vary according to the manner inwhich the composition is to be applied, but in general comprises 0.5 to95% of active ingredient by weight of the insecticidal composition.

Flowable formulations are similar to ECs, except that the activeingredient is suspended in a liquid carrier, generally water. Flowables,like ECs, may include a small amount of a surfactant, and will typicallycontain active ingredients in the range of 0.5 to 95%, frequently from10 to 50%, by weight of the composition. For application, flowables maybe diluted in water or other liquid vehicle, and are normally applied asa spray to the area to be treated.

Typical wetting, dispersing or emulsifying agents used in agriculturaland/or horticultural formulations include, but are not limited to, thealkyl and alkylaryl sulfonates and sulfates and their sodium salts;alkylaryl polyether alcohols; sulfated higher alcohols; polyethyleneoxides; sulfonated animal and vegetable oils; sulfonated petroleum oils;fatty acid esters of polyhydric alcohols and the ethylene oxide additionproducts of such esters; and the addition product of long-chainmercaptans and ethylene oxide. Many other types of useful surface-activeagents are available in commerce. Surface-active agents, when used,normally comprise 1 to 15% by weight of the composition.

Other useful formulations include suspensions of the active ingredientin a relatively non-volatile solvent such as water, corn oil, kerosene,propylene glycol, or other suitable solvents.

Still other useful formulations for insecticidal applications includesimple solutions of the active ingredient in a solvent in which it iscompletely soluble at the desired concentration, such as acetone,alkylated naphthalenes, xylene, or other organic solvents. Granularformulations, wherein the active ingredient is carried on relativecoarse particles, are of particular utility for aerial distribution orfor penetration of cover crop canopy. Pressurized sprays, typicallyaerosols wherein the active ingredient is dispersed in finely dividedform as a result of vaporization of a low-boiling dispersant solventcarrier may also be used. Water-soluble or water-dispersible granulesare free flowing, non-dusty, and readily water-soluble orwater-miscible. In use by the farmer on the field, the granularformulations, emulsifiable concentrates, flowable concentrates, aqueousemulsions, solutions, etc., may be diluted with water to give aconcentration of active ingredient in the range of say 0.1% or 0.2% to1.5% or 2%.

By far the most frequently used are water-miscible formulations formixing with water then applying as sprays. Water miscible, olderformulations include: emulsifiable concentrate, wettable powder, soluble(liquid) concentrate, and soluble powder. Newer, non-powderyformulations with reduced or no hazardous solvents and improvedstability include: suspension concentrate, capsule suspensions, waterdispersible granules. Such formulations are preferably solutions andsuspension, e.g., aqueous suspension and solutions, ethanolic suspensionand solutions, aqueous/ethanolic suspension and solutions, salinesolutions, and colloidal suspensions.

Alternatively, a sprayable wax emulsion formulation can be used. Theformulation contains the active ingredient, in an amount from about0.01% to 75% by weight. The aqueous wax emulsions are broadly describedin U.S. Pat. No. 6,001,346, which is hereby incorporated by reference inis entirety. The TRPA1 inhibitors of the methods described herein canhave a viscosity appropriate for use in aerial or backpack sprayapplications.

The biodegradable wax carrier comprises at least about 10% by weight ofthe formulation. The biodegradable wax carrier is selected from thegroup consisting of paraffin, beeswax, vegetable based waxes such assoywax (soybean based), and hydrocarbon based waxes such as Gulf WaxHousehold Paraffin Wax; paraffin wax, avg. m.p. 53C (hexacosane), highmolecular weight hydrocarbons). carnauba wax, lanolin, shellac wax,bayberry wax, sugar cane wax, microcrystalline, ozocerite, ceresin,montan, candelilla wax, and combinations thereof.

Formulations can contain an emulsifier in an amount from about 1% toabout 10% by weight. Suitable emulsifiers include lecithin and modifiedlecithins, mono- and diglycerides, sorbitan monopalmitate, sorbitanmonooleate, sorbitan monolaurate, polyoxyethylene-sorbitan monooleate,fatty acids, lipids, etc. The emulsifiers provide or improveemulsification properties of the composition. The emulsifier can beselected from many products which are well known in the art, including,but not limited to, sorbitan monolaurate (anhydrosorbitol stearate,molecular formula C₂₄H₄₆O₆), ARLACEL 60, ARMOTAN MS, CRILL 3, CRILL K3,DREWSORB 60, DURTAN 60, EMSORB 2505, GLYCOMUL S, HODAG SMS, IONET S 60,LIPOSORB S, LIPOSORB S-20, MONTANE 60, MS 33, MS33F, NEWCOL 60, NIKKOLSS 30, NISSAN NONION SP 60, NONION SP 60, NONION SP 60R, RIKEMAL S 250,sorbitan c, sorbitan stearate, SORBON 60, SORGEN 50, SPAN 55, AND SPAN60; other sorbitan fatty acid ester that may be used include sorbitanmonopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitanmonooleate, sorbitan sesquioleate, sorbitan trioleate, sorbitanmonooleate, sorbitan trioleate. In certain embodiments, SPAN 60 ispreferred.

In certain embodiments, formulations can includes a phagostimulant, suchas corn oil, molasses, glycerol, or corn syrup, proteinaceous material(protein or hydrolyzed protein), sugars like sucrose, or food-basedingredients such as trimethylamine, putrescine, bacterial or yeastvolatiles or metabolites, ammonium acetate, ammonium carbonate or otherammonia-emitting compounds. Acetic acid vapor can be provided bycompounds that produce volatilized acetic acid, for example, aqueousacetic acid, glacial acetic acid, glacial (concentrated) acetic acid, orammonium producing compounds such as but not restricted to ammoniumhydroxide, ammonium carbonate, ammonium bicarbonate, ammonium acetate,etc. Ammonium acetate is most preferred for providing acetic acid andammonia vapors.

The active ingredient, may be formulated and/or applied with one or moresecond compounds. Various combinations TRPA1 inhibitors and TRPA1agonists can be used to obtain greater advantage. For example both aTRPA1 inhibitor and TRPA1 agonist are applied at the same time. In oneembodiment, a formulation described herein comprises both a TRPA1inhibitor and a TRPA1 agonist. In one embodiment, two or more activeagents are formulated together. In one embodiment, two or more activeagents formulated together are all either TRPA1 inhibitors or are allTRPA1 agonists. Such combinations may provide certain advantages, suchas, without limitation, exhibiting synergistic effects for greatercontrol of insects or non-insect pests, reducing rates of applicationthereby minimizing any impact to the environment and to worker safety,controlling a broader spectrum of insects and non-insect pests, andimproving tolerance by non-pest species, such as mammals and fish. Othersecond compounds include, without limitation, insecticides, pesticides,plant growth regulators, fertilizers, soil conditioners, or otheragricultural and horticultural chemicals. The formulation may includesuch second compounds in an amount from about 0.002% to about 25% byweight of the composition.

Insecticides include, but are not limited to, organophosphateinsecticides, such as chlorpyrifos, diazinon, dimethoate, malathion,parathion-methyl, naled, and terbufos; nicotinic insecticides such asimidacloprid and thiacloprid; pyrethroid insecticides, such asfenvalerate, delta-methrin, fenpropathrin, cyfluthrin, flucythrinate,alpha-cypermethrin, biphenthrin, resolved cyhalothrin, etofenprox,esfenvalerate, tralomethrin, tefluthrin, cycloprothrin, betacyfluthrin,and acrinathrin; carbamate insecticides, such as aldecarb, carbaryl,carbofuran, and methomyl; organochlorine insecticides, such asendosulfan, endrin, heptachlor, and lindane; benzoylurea insecticides,such as diflubenuron, triflumuron, teflubenzuron, chlorfluazuron,flucycloxuron, hexaflumuron, flufenoxuron, dimlin, novaluron, andlufenuron; diacylhydrazines such as methoxyfenozide; phenylpyrazolessuch as fipronil or ethiprole, chlorfenapyr, diafenthiuron, indoxacarb,metaflumazone, emamectin benzoate, abamectin, pyridalyl, flubendiamide,rynaxypyr; and other insecticides, such as amitraz, clofentezine,fenpyroximate, hexythiazox, spinosad, and imidacloprid.

Pesticide include, but are not limited to, benzimidazine fungicides,such as benomyl, carbendazim, thia-bendazine, and thiophanate-methyl;1,2,4-triazine fungicides, such as epoxyconazine, cyproconazine,flusilazine, flutriafol, propiconazine, tebuconazine, triadimefon, andtri-adimenol; substituted anilide fungicides, such as metalaxyl,oxadixyl, procymidone, and vinclozolin; organophosphorus fungicides,such as fosetyl, iprobenfos, pyrazophos, edifen-phos, andtolclofos-methyl; morpholine fungicides, such as fenpropimorph,tridemorph, and dodemorph; other systemic fungicides, such as fenarimol,imazalil, prochloraz, tricycla-zine, and triforine; dithiocarbamatefungicides, such as mancozeb, maneb, propineb, zineb, and ziram;non-systemic fungicides, such as chlorothalonil, dichlorofluanid,dithianon, and iprodione, captan, dinocap, dodine, fluazinam,gluazatine, PCNB, pencycuron, quintozene, tricylamide, and validamycin;inorganic fungicides, such as copper and sulphur products, and otherfungicides; nematicides such as carbofuran, carbosulfan, turbufos,aldecarb, ethoprop, fenamphos, oxamyl, isazofos, cadusafos, and othernematicides.

Formulations can contain visual attractants, e.g. food coloring.

A variety of additives may be incorporated into the formulation. Theseadditives typically change and/or enhance the physical characteristicsof the carrier material and are, therefore, suitable for designingcompositions having specific requirements as to the release rate andamount of the active ingredient, protection of the wax composition fromweather conditions, etc. These additives are, among others,plasticizers, volatility suppressants, antioxidants, lipids, variousultraviolet blockers and absorbers, or antimicrobials, typically addedin amounts from about 0.001% to about 10%, more typically between 1-6%,by weight.

Plasticizers, such as glycerin or soy oil affect physical properties ofthe composition and may extend its resistance to environmentaldestruction.

Antioxidants, such as vitamin E, BHA (butylated hydroxyanisole), BHT(butylated hydroxytoluene), and other antioxidants which protect thebioactive agent from degradation, may be added in amounts from about0.1% to about 3%, by weight.

Ultraviolet blockers, such as beta-carotene, lignin or p-aminobenzoicacid protect the bioactive agents from light degradation may be added inamounts from about 1% to about 3%, by weight.

Antimicrobials, such as potassium sorbate, nitrates, nitrites, andpropylene oxide, protect the bioactive agents from microbial destructionmay be added in amounts from 0.1% to about 2% by weight.

Adjuvants can also be added to the formulation. An adjuvant is broadlydefined as any substance added to the spray tank, separate from thepesticide formulation, that will improve the performance of thepesticide. These includes but are not limited to wetter-spreaders,stickers, penetrants, compatibility agents, buffers, and so on.

Other compounds and materials can be added provided they do notsubstantially interfere with the activity of active ingredient. Whetheror not an additive substantially interferes with the active ingredient'sactivity can be determined by standard test formats, involving directcomparisons of efficacy of the composition of the active ingredientwithout an added compound and the composition of the active ingredientwith an added compound.

In one embodiment, the active ingredient is preferably applied topicallyon a subject at risk of insect bites. The active ingredient is appliedin therapeutically effective amount in admixture with pharmaceuticalcarriers, in the form of topical pharmaceutical compositions. Suchcompositions include solutions, suspensions, lotions, gels, creams,ointments, emulsions, sprays, etc. All of these dosage forms, along withmethods for their preparation, are well known in the pharmaceutical andcosmetic art and described, for example in, Harry's Cosmeticology(Chemical Publishing, 8th ed. 2000) and Remington's PharmaceuticalSciences (Mack Publishing Co., 18th ed. 1990), contents of both of whichare incorporated herein by reference in their entirety. Typically, suchtopical formulations contain the active ingredient in a concentrationrange of 0.001 to 10 mg/ml, in admixture with suitable vehicles. Otherdesirable ingredients that can be added to the topical preparationsinclude preservatives, co-solvents, viscosity building agents, carriers,etc.

Penetration enhancers may, for example, be surface active agents;certain organic solvents, such as di-methylsulfoxide and othersulfoxides, dimethyl-acetamide and pyrrolidone; certain amides ofheterocyclic amines, glycols (e.g. propylene glycol); propylenecarbonate; oleic acid; alkyl amines and derivatives; various cationic,anionic, nonionic, and amphoteric surface active agents; and the like.

Frequently used carriers or auxiliaries include magnesium carbonate,titanium dioxide, lactose, mannitol and other sugars, talc, milkprotein, gelatin, starch, vitamins, cellulose and its derivatives,animal and vegetable oils, polyethylene glycols and solvents, such assterile water, alcohols, glycerol and polyhydric alcohols.

Preservatives include antimicrobial, anti-oxidants, chelating agents andinert gases. Other pharmaceutically acceptable carriers include aqueoussolutions, non-toxic excipients, including salts, preservatives, buffersand the like, as described, for instance, in Remington's PharmaceuticalSciences (Mack Publishing Co., 18^(th) ed., 1990), content of which isincorporated herein by reference in its entirety. The pH and exactconcentration of the various components of the pharmaceuticalcomposition are adjusted according to routine skills in the art. SeeGoodman and Gilman's The Pharmacological Basis for Therapeutics(McGraw-Hill Professional, 10^(th) ed., 2001), content of which isincorporated herein by reference in its entirety.

Excipients include those described, for example, in Handbook ofPharmaceutical Excipients (Pharmaceutical Press, 6^(th) ed., 1990),content of which is incorporated herein by reference in its entirety.

Inventors have discovered that an insect will stop eating afteringesting a TRPA1 activating compound. For example ingesting a TRPA1 iongated channel agonist can cause an insect to stop eating. Thus, in oneembodiment, the compounds are formulated with a food source for insects,e.g., formulated with compounds in insect diet. In another embodiment,the compounds are formulated with sucrose. Without wishing to be boundby theory, the insect will feed on such mixtures and stop eating.

In some embodiments, the compound can be applied to breeding locus ofinsects. Without wishing to be bound by theory, application of activeagent to breeding locus inhibits insects from breeding by eitherrepelling them from that locus or preventing laying of eggs at thatlocus, or both.

In another embodiment, the active agent is applied to feeding locus ofinsects. This inhibits insect feeding leading to starvation of insects.

In yet another embodiment, the active agent is applied to both breedingand feeding locus of insects.

In one embodiment, the active agent is applied as a spray to locus ofinsects, e.g., breeding locus, feeding locus.

In one embodiment, the active agent is applied to insect traps. Forexample, the trap may be coated with the active agent or trap may beloaded with insect food comprising an active agent.

In one embodiment, the active agent is applied to clothing, such as ashirt, hat, pants, shorts, outer garment, etc. . . . of a subject. Inone embodiment, the active agent is applied to clothing by soaking theclothing in a solution comprising the active agent. In anotherembodiment, the active agent is applied to clothing by spraying theclothing with a formulation comprising the active agent.

DEFINITIONS

Unless otherwise explained, all technical and scientific terms usedherein have the same meaning as commonly understood by one of ordinaryskill in the art to which this disclosure belongs. Definitions of commonterms in neurobiology and molecular biology can be found in The MerckManual of Diagnosis and Therapy, 18th Edition, published by MerckResearch Laboratories, 2006 (ISBN 0-911910-18-2); Robert S. Porter etal. (eds.), The Encyclopedia of Molecular Biology, published byBlackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers(ed.), Molecular Biology and Biotechnology: a Comprehensive DeskReference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8);The ELISA guidebook (Methods in molecular biology 149) by Crowther J. R.(2000); Fundamentals of RIA and Other Ligand Assays by Jeffrey Travis,1979, Scientific Newsletters; Immunology by Werner Luttmann, publishedby Elsevier, 2006. Definitions of common terms in molecular biology maybe found in Benjamin Lewin, Genes IX, published by Jones & BartlettPublishing, 2007 (ISBN-13: 9780763740634); Kendrew et al. (eds.), TheEncyclopedia of Molecular Biology, published by Blackwell Science Ltd.,1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biologyand Biotechnology: a Comprehensive Desk Reference, published by VCHPublishers, Inc., 1995 (ISBN 1-56081-569-8).

Unless otherwise stated, experiments detailed herein were performedusing standard procedures, as described, for example in Maniatis et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y., USA (1982); Sambrook et al., MolecularCloning: A Laboratory Manual (2 ed.), Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y., USA (1989); Davis et al., Basic Methodsin Molecular Biology, Elsevier Science Publishing, Inc., New York, USA(1986); or Methods in Enzymology: Guide to Molecular Cloning TechniquesVol. 152, S. L. Berger and A. R. Kimmerl Eds., Academic Press Inc., SanDiego, USA (1987)).

Current Protocols in Molecular Biology (CPMB) (Fred M. Ausubel, et al.ed., John Wiley and Sons, Inc.), Current Protocols in Protein Science(CPPS) (John E. Coligan, et. al., ed., John Wiley and Sons, Inc.) andCurrent Protocols in Immunology (CPI) (John E. Coligan, et. al., ed.John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB)(Juan S. Bonifacino et. al. ed., John Wiley and Sons, Inc.), Culture ofAnimal Cells: A Manual of Basic Technique by R. Ian Freshney, Publisher:Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods inCell Biology, Vol 57, Jennie P. Mather and David Barnes editors,Academic Press, 1st edition, 1998) which are all incorporated byreference herein in their entireties.

It should be understood that this invention is not limited to theparticular methodology, protocols, and reagents, etc., described hereinand as such may vary. The terminology used herein is for the purpose ofdescribing particular embodiments only, and is not intended to limit thescope of the present invention, which is defined solely by the claims.

Other than in the operating examples, or where otherwise indicated, allnumbers expressing quantities of ingredients or reaction conditions usedherein should be understood as modified in all instances by the term“about.” The term “about” when used in connection with percentages maymean±1%.

The singular terms “a,” “an,” and “the” include plural referents unlesscontext clearly indicates otherwise. Similarly, the word “or” isintended to include “and” unless the context clearly indicatesotherwise.

As used herein the term “comprising” or “comprises” is used in referenceto compositions, methods, and respective component(s) thereof, that areessential to the invention, yet open to the inclusion of unspecifiedelements, whether essential or not. The term “comprises” means“includes.” The abbreviation, “e.g.” is derived from the Latin exempligratia, and is used herein to indicate a non-limiting example. Thus, theabbreviation “e.g.” is synonymous with the term “for example.”

As used herein the term “consisting essentially of” refers to thoseelements required for a given embodiment. The term permits the presenceof additional elements that do not materially affect the basic and novelor functional characteristic(s) of that embodiment of the invention.

The term “consisting of” refers to compositions, methods, and respectivecomponents thereof as described herein, which are exclusive of anyelement not recited in that description of the embodiment.

Although methods and materials similar or equivalent to those describedherein can be used in the practice or testing of this disclosure,suitable methods and materials are described below.

The terms “decrease”, “reduced”, “reduction”, “decreased” or “inhibit”are all used herein generally to mean a decrease by a statisticallysignificant amount. However, for avoidance of doubt, ““reduced”,“reduction” or “decrease” or “inhibit” means a decrease by at least 10%as compared to a reference level, for example a decrease by at leastabout 20%, or at least about 30%, or at least about 40%, or at leastabout 50%, or at least about 60%, or at least about 70%, or at leastabout 80%, or at least about 90% or up to and including a 100% decrease(e.g. absent level as compared to a reference sample), or any decreasebetween 10-100% as compared to a reference level.

The terms “increased”, “increase” or “enhance” or “activate” are allused herein to generally mean an increase by a statically significantamount; for the avoidance of any doubt, the terms “increased”,“increase” or “enhance” or “activate” means an increase of at least 10%as compared to a reference level, for example an increase of at leastabout 20%, or at least about 30%, or at least about 40%, or at leastabout 50%, or at least about 60%, or at least about 70%, or at leastabout 80%, or at least about 90% or up to and including a 100% increaseor any increase between 10-100% as compared to a reference level, or atleast about a 2-fold, or at least about a 3-fold, or at least about a4-fold, or at least about a 5-fold or at least about a 10-fold increase,or any increase between 2-fold and 10-fold or greater as compared to areference level.

The term “statistically significant” or “significantly” refers tostatistical significance and generally means a two standard deviation(2SD) change from a reference level. The term refers to statisticalevidence that there is a difference. It is defined as the probability ofmaking a decision to reject the null hypothesis when the null hypothesisis actually true. The decision is often made using the p-value.

As used herein, the term “peptide” is used in its broadest sense torefer to compounds containing amino acids, amino acid equivalents orother non-amino groups, while still retaining the desired functionalactivity of a peptide. Peptide equivalents can differ from conventionalpeptides by the replacement of one or more amino acids with relatedorganic acids (such as PABA), amino acids or the like or thesubstitution or modification of side chains or functional groups. Thepeptides can be linear or cyclic. A peptide can be modified to includeone or more of D-amino acids, beta-amino acids, chemically modifiedamino acids, naturally occurring non-proteogenic amino acids, rare aminoacids, and chemically synthesized compounds that have properties knownin the art to be characteristic of an amino acid. As used herein, theterm “proteogenic” indicates that the amino acid can be incorporatedinto a protein in a cell through well-known metabolic pathways.

As used herein, the term “nucleic acid” or “oligonucleotide” orgrammatical equivalents herein means at least two nucleotides, includinganalogs or derivatives thereof, that are covalently linked together. Thenucleic acids can be single stranded or double stranded. The nucleicacid can be DNA, RNA or a hybrid, where the nucleic acid contains anycombination of deoxyribo- and ribo-nucleotides, and any combination ofuracil, adenine, thymine, cytosine and guanine. The nucleic acids cancomprise one or more backbone modifications, e.g., phosphoramide(Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein;Letsinger, J. Org. Chem. 35:3800 (1970)), phosphorothioate,phosphorodithioate, O-methylphosphoroamidite linkages (see Eckstein,Oligonucleotides and Analogues: A Practical Approach, Oxford UniversityPress), or peptide nucleic acid linkages (see Egholm, J. Am. Chem. Soc.114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992);Nielsen, Nature, 365:566 (1993)). The nucleic acids can also includemodifications to nucleobase and/or sugar moieties of nucleotides.Exemplary sugar modifications at the sugar moiety include replacement of2′-OH with halogens (e.g., fluoro), O-methyl, O-methoxyethyl, NH₂, SHand S-methyl.

As used herein, the term “polysaccharide” refers to macromolecularcarbohydrates whose molecule consists of a large number ofmonosaccharide molecules which are joined to one another by glycosidiclinkage. Polysaccharides are classified by dividing them into. The termpolysaccharide is also intended to embrace an oligosaccharide. Thepolysaccharide can be homopolysaccharides or heteropolysaccharides.Whereas the homopolysaccharides contain only one kind of unit, theheteropolysaccharides consist of monomer units of different kinds.

As used here in the term “isomer” refers to compounds having the samemolecular formula but differing in structure. Isomers which differ onlyin configuration and/or conformation are referred to as “stereoisomers.”The term “isomer” is also used to refer to an enantiomer.

The term “analog” as used herein refers to a compound that results fromsubstitution, replacement or deletion of various organic groups orhydrogen atoms from a parent compound. As such, some monoterpenoids canbe considered to be analogs of monoterpenes, or in some cases, analogsof other monoterpenoids, including derivatives of monoterpenes. Ananalog is structurally similar to the parent compound, but can differ byeven a single element of the same valence and group of the periodictable as the element it replaces.

The term “derivative” as used herein refers to a chemical substancerelated structurally to another, i.e., an “original” substance, whichcan be referred to as a “parent” compound. A “derivative” can be madefrom the structurally-related parent compound in one or more steps. Thephrase “closely related derivative” means a derivative whose molecularweight does not exceed the weight of the parent compound by more than50%. The general physical and chemical properties of a closely relatedderivative are also similar to the parent compound.

As used herein, a “prodrug” refers to compounds that can be convertedvia some chemical or physiological process (e.g., enzymatic processesand metabolic hydrolysis) to a therapeutic agent. Thus, the term“prodrug” also refers to a precursor of a biologically active compoundthat is pharmaceutically acceptable. A prodrug may be inactive whenadministered to a subject, i.e. an ester, but is converted in vivo to anactive compound, for example, by hydrolysis to the free carboxylic acidor free hydroxyl. The prodrug compound often offers advantages ofsolubility, tissue compatibility or delayed release in an organism. Theterm “prodrug” is also meant to include any covalently bonded carriers,which release the active compound in vivo when such prodrug isadministered to a subject. Prodrugs of an active compound may beprepared by modifying functional groups present in the active compoundin such a way that the modifications are cleaved, either in routinemanipulation or in vivo, to the parent active compound. Prodrugs includecompounds wherein a hydroxy, amino or mercapto group is bonded to anygroup that, when the prodrug of the active compound is administered to asubject, cleaves to form a free hydroxy, free amino or free mercaptogroup, respectively. Examples of prodrugs include, but are not limitedto, acetate, formate and benzoate derivatives of an alcohol oracetamide, formamide and benzamide derivatives of an amine functionalgroup in the active compound and the like. See Harper, “DrugLatentiation” in Jucker, ed. Progress in Drug Research 4:221-294 (1962);Morozowich et al, “Application of Physical Organic Principles to ProdrugDesign” in E. B. Roche ed. Design of Biopharmaceutical Propertiesthrough Prodrugs and Analogs, APHA Acad. Pharm. Sci. 40 (1977);Bioreversible Carriers in Drug in Drug Design, Theory and Application,E. B. Roche, ed., APHA Acad. Pharm. Sci. (1987); Design of Prodrugs, H.Bundgaard, Elsevier (1985); Wang et al. “Prodrug approaches to theimproved delivery of peptide drug” in Curr. Pharm. Design. 5(4):265-287(1999); Pauletti et al. (1997) Improvement in peptide bioavailability:Peptidomimetics and Prodrug Strategies, Adv. Drug. Delivery Rev.27:235-256; Mizen et al. (1998) “The Use of Esters as Prodrugs for OralDelivery of (3-Lactam antibiotics,” Pharm. Biotech. 11:345-365;Gaignault et al. (1996) “Designing Prodrugs and Bioprecursors I. CarrierProdrugs,” Pract. Med. Chem. 671-696; Asgharnejad, “Improving Oral DrugTransport”, in Transport Processes in Pharmaceutical Systems, G. L.Amidon, P. I. Lee and E. M. Topp, Eds., Marcell Dekker, p. 185-218(2000); Balant et al., “Prodrugs for the improvement of drug absorptionvia different routes of administration”, Eur. J. Drug Metab.Pharmacokinet., 15(2): 143-53 (1990); Balimane and Sinko, “Involvementof multiple transporters in the oral absorption of nucleosideanalogues”, Adv. Drug Delivery Rev., 39(1-3): 183-209 (1999); Browne,“Fosphenyloin (Cerebyx)”, Clin. Neuropharmacol. 20(1): 1-12 (1997);Bundgaard, “Bioreversible derivatization of drugs—principle andapplicability to improve the therapeutic effects of drugs”, Arch. Pharm.Chemi 86(1): 1-39 (1979); Bundgaard H. “Improved drug delivery by theprodrug approach”, Controlled Drug Delivery 17: 179-96 (1987); BundgaardH. “Prodrugs as a means to improve the delivery of peptide drugs”, Arfv.Drug Delivery Rev. 8(1): 1-38 (1992); Fleisher et al. “Improved oraldrug delivery: solubility limitations overcome by the use of prodrugs”,Arfv. Drug Delivery Rev. 19(2): 115-130 (1996); Fleisher et al. “Designof prodrugs for improved gastrointestinal absorption by intestinalenzyme targeting”, Methods Enzymol. 112 (Drug Enzyme Targeting, Pt. A):360-81, (1985); Farquhar D, et al., “Biologically ReversiblePhosphate-Protective Groups”, Pharm. Sci., 72(3): 324-325 (1983);Freeman S, et al., “Bioreversible Protection for the Phospho Group:Chemical Stability and Bioactivation of Di(4-acetoxy-benzyl)Methylphosphonate with Carboxyesterase,” Chem. Soc., Chem. Commun.,875-877 (1991); Friis and Bundgaard, “Prodrugs of phosphates andphosphonates: Novel lipophilic alphaacyloxyalkyl ester derivatives ofphosphate- or phosphonate containing drugs masking the negative chargesof these groups”, Eur. J. Pharm. Sci. 4: 49-59 (1996); Gangwar et al.,“Pro-drug, molecular structure and percutaneous delivery”, Des.Biopharm. Prop. Prodrugs Analogs, [Symp.] Meeting Date 1976, 409-21.(1977); Nathwani and Wood, “Penicillins: a current review of theirclinical pharmacology and therapeutic use”, Drugs 45(6): 866-94 (1993);Sinhababu and Thakker, “Prodrugs of anticancer agents”, Adv. DrugDelivery Rev. 19(2): 241-273 (1996); Stella et al., “Prodrugs. Do theyhave advantages in clinical practice?”, Drugs 29(5): 455-73 (1985); Tanet al. “Development and optimization of anti-HIV nucleoside analogs andprodrugs: A review of their cellular pharmacology, structure-activityrelationships and pharmacokinetics”, Adv. Drug Delivery Rev. 39(1-3):117-151 (1999); Taylor, “Improved passive oral drug delivery viaprodrugs”, Adv. Drug Delivery Rev., 19(2): 131-148 (1996); Valentino andBorchardt, “Prodrug strategies to enhance the intestinal absorption ofpeptides”, Drug Discovery Today 2(4): 148-155 (1997); Wiebe and Knaus,“Concepts for the design of anti-HIV nucleoside prodrugs for treatingcephalic HIV infection”, Adv. Drug Delivery Rev.: 39(1-3):63-80 (1999);Waller et al., “Prodrugs”, Br. J. Clin. Pharmac. 28: 497-507 (1989),content of all of which is herein incorporated by reference in itsentirety.

The term “pharmaceutically acceptable salt” is a salt of a compound ofthe invention that retains the biological effectiveness and propertiesof the compound of the invention and which is not biologically orotherwise undesirable. Salts may be derived from inorganic or organicacids and bases, and include pharmaceutically acceptable anions, theanions of acid addition salts, and pharmaceutically acceptable cations,the cations of base addition salts. Acid addition salts are derived frominorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuricacid (giving the sulfate and bisulfate salts), nitric acid, phosphoricacid and the like, and organic acids such as acetic acid, propionicacid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonicacid, succinic acid, maleic acid, fumaric acid, tartaric acid, citricacid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid,ethanesulfonic acid, salicylic acid, p-toluenesulfonic acid, and thelike. Base addition salts may be derived from inorganic bases such assodium hydroxide, potassium hydroxide, lithium hydroxide, ammonium,calcium hydroxide, magnesium hydroxide, and the like. Salts derived fromorganic bases include those formed from primary, secondary, and tertiaryamines, substituted amines including naturally occurring substitutedamines, including isopropylamine, trimethylamine, diethylamine,triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol,cyclohexylamine, pyridine, ethylenediamine, tromethamine, lysine,arginine, histidine, caffeine, procaine hydrabamine choline, betaine,glucosamine, N-alkylglucamines, theobromine, purines, piperazine,piperidine, N-ethylpiperidine, and the like.

As used herein, the term “EC50,” refers to the concentration of acompound that produces 50% of maximal activation of a TRPA1 activitymeasurable using the same assay in the absence of the compound. Stateddifferently, the “EC50” is the concentration of a compound that gives50% activation, when 100% activation is set at the amount of activitythat does not increase with the addition of more of the compound. TheEC50 can be as measured in vitro or in vivo.

As used herein, the term “IC50” refers to the concentration of acompound that produces 50% of the maximal inhibition of an TRPA1activity measurable using the same assay in the absence of saidcompound. The IC50 can be as measured in vitro or in vivo.

To the extent not already indicated, it will be understood by those ofordinary skill in the art that any one of the various embodiments hereindescribed and illustrated may be further modified to incorporatefeatures shown in any of the other embodiments disclosed herein.

The following examples illustrate some embodiments and aspects of theinvention. It will be apparent to those skilled in the relevant art thatvarious modifications, additions, substitutions, and the like can beperformed without altering the spirit or scope of the invention, andsuch modifications and variations are encompassed within the scope ofthe invention as defined in the claims which follow. The followingexamples do not in any way limit the invention.

The present invention may be defined in any of the followingsubparagraphs:

In one aspect, the invention provides a method of identifying aninsect-specific TRPA1 modulator comprising: (a) contacting a testcompound with an insect TRPA1 and a vertebrate TRPA1; and (b) assayingmodulation of insect and vertebrate TRPA1 activity.

In some embodiments, the method further contains the step of selectingthe test compound that modulates the activity of insect TRPA1 by atleast 10% relative to the mammalian TRPA1.

In some other embodiments, the compound inhibits the activity of theinsect TRPA1.

In still other embodiments, the compound activates the insect TRPA1.

In some embodiments, the insect TRPA1 is selected from the groupconsisting of D. melanogaster TRPA1 isoform F (Accession No. ABW08500.3)(SEQ ID NO: 1), D. melanogaster TRPA1 isoform E (Accession No.AAF50356.4) (SEQ ID NO: 2), D. melanogaster TRPA1 isoform F (AccessionNo. NP_001097554.3) (SEQ ID NO: 3), D. melanogaster TRPA1 isoform E(Accession No. NP_648263.4) (SEQ ID NO: 4), D. melanogaster TRPA 1(Accession No. Q7Z020.3) (SEQ ID NO: 5), Anopheles gambiae TRPA1(Accession No. ACC86138.1) (SEQ ID NO: 6), Tribolium castaneumhypothetical protein TcasGA2_TC002449 (Accession No. EFA01253.1) (SEQ IDNO: 7), and conservative variants thereof.

In some embodiments, the vertebrate TRPA1 is selected from the groupconsisting of Rattus norvegicus transient receptor potential cationchannel, subfamily A, member 1 (Accession No. NP_997491.1) (SEQ ID NO:8); Rattus norvegicus transient receptor potential cation channelsubfamily A member 1 (Accession No. AAS78661.1) (SEQ ID NO: 9); Musmusculus transient receptor potential cation channel, subfamily A,member 1 (Accession No. NP_808449.1) (SEQ ID NO: 10); Homo sapienstransient receptor potential cation channel subfamily A member 1(Accession No. NP_015628.2) (SEQ ID NO: 11); Mus musculus transientreceptor potential cation channel, subfamily A, member 1 (Accession No.AAI31964.1) (SEQ ID NO: 12); Mus musculus transient

receptor potential cation channel, subfamily A, member 1 (Accession No.AAI20564.1) (SEQ ID NO: 13); Mus musculus transient receptor potentialcation channel, subfamily A, member 1, isoform CRA_b (Accession No.EDL14332.1) (SEQ ID NO: 14); Mus musculus transient receptor potentialcation channel, subfamily A, member 1, isoform CRA_a (Accession No.EDL14331.1) (SEQ ID NO: 15); Bos Taurus transformation sensitive proteinp120 (Accession No. XP_581588.2) (SEQ ID NO: 16); Pan troglodytespredicted ankyrinlike protein 1 (Accession No. XP_519806.2) (SEQ ID NO:17); Macaca mulatta predicted ankyrinlikeprotein 1 (Accession No. XP_001083172.1) (SEQ ID NO: 18); Gallus galluspredicted similar to transient receptor potential cation channelsubfamily A member 1 (Accession No. XP_418294.2) (SEQ ID NO: 19); Daniorerio TRPA1 (Accession No. AAV37177.1) (SEQ ID NO: 20), Danio reriotransient receptor potential cation channel, subfamily A, member 1a(Accession No. NP_001007066.1) (SEQ ID NO: 21), and conservativevariants thereof.

In some embodiments, the test compound is selected from the groupconsisting of small organic molecule, small inorganic molecule,polysaccharides, peptides, proteins, nucleic acids, an extract made frombiological materials such as bacteria, plants, fungi, animal cells,animal tissues, and any combinations thereof.

In some other embodiments, the test compound is synthetic compound.

In some embodiments, the test compound is unpurified.

In some other embodiments, the test compound has a molecular weight ofless than 5000 Daltons (5 kD).

In still other embodiments, the test compound is tested at aconcentration in the range of about 0.1 nM to about 1000 mM.

In some embodiments, the insect TRPA1 is inside a cell.

In some embodiments, the vertebrate mammalian TRPA1 is inside a cell.

In some other embodiments, the cell is an oocyte.

In some embodiments, the oocyte is an Xenopus lavis oocyte.

In another aspect, the invention provides a compound selected by themethod of any of the aspects delineated herein.

In yet another aspect, the invention provides a method of insect controlcomprising applying to an insect a compound selected by the method ofany of the aspects delineated herein.

In various embodiments, the compound is an inhibitor of TRPA1.

In some embodiments, the compound has an IC50 value of less than 500 nM.

In some other embodiments, the compound is an activator of TRPA1.

In still other embodiments, the compound has and EC50 value of less than500 nM.

In various embodiments, the insect is selected from the group consistingof fleas, rat fleas, oriental rat fleas, flies, black flies, sand flies,mosquitoes, horse flies, deer flies, eye gnats, house flies, blow flies,flesh flies, tsetse flies, lice, human lice, true bugs, assassin bugs,kissing bugs, and any combinations thereof.

In some embodiments, the insect is a disease vector.

In some other embodiments, the insect is an agricultural/horticulturalpest.

In still other embodiments, the insect is a parasite.

In some embodiments, the compound is applied as a spray.

In some embodiments, the compound is applied topically.

In some embodiments, the compound is applied directly to adult insects.

In some other embodiments, the compound is applied to a locus ofinsects.

In some embodiments, locus is a breeding locus.

In still other embodiments, the locus is a feeding locus.

In some embodiments, the compound is formulated with a food source.

In some other embodiments, the compound is formulated with sucrose.

In still other embodiments, the compound modulates thermo- and/orchemo-sensing in the insect.

EXAMPLES Methods

Proboscis Extension Behavior.

The proboscis extension assay was modified from ones previouslydescribed in Thorne, et al., Curr Biol 14, 1065-1079 (2004) and Wang, etal., Scott, Cell 117, 981-991 (2004) and as detailed in herein.

Physiology.

Oocyte and larval physiology were performed largely as described inHamada, et al., Nature 454, 217-220 (2008) and Pulver, et al., JNeurophysiol 101, 3075-3088 (2009), with additional details provided inbelow. Chemical sensitivities of wild type and mutant (dTRPA1-2C)channels were assessed by normalizing all currents to currents observedat 1 mM AITC. Chemically unrelated insect repellents like DEET, IR-3535,and deltamethrin failed to activate dTRPA1 (data not shown).

Phylogeny.

TRPA sequences were assembled from available genomic and EST data.Multiple sequence alignment was performed using ProbCons (Do, C. B., M.S. Mahabhashyam, M. Brudno, and S. Batzoglou, Genome Res 15, 330-340(2005)) for region from ˜310 amino acids N-terminal of transmembraneregions (containing the residues implicated in chemical sensing) to ˜50amino acids C-terminal of transmembrane regions (Data not shown).Bayesian analysis was calculated with the parallel version of MrBayes3.1.2 using mixed substitution rate matrices and gamma distributed ratevariation across sites (8 categories). An exponential prior (mean=1.0)was assumed for shape parameter of the gamma distribution, anunconstrained exponential prior (mean=1.0) assumed for branch lengths,and a uniform prior assumed for all labeled topologies. Two independentMCMC analyses were performed (each with one cold and three heatedchains), with other parameters set to defaults. Chains were run for10,000,000 generations, and convergence inferred after cold chaintopologies reached a standard deviation of split frequencies of lessthan 0.005 (˜250,000 generations). After convergence, the first half ofthe chain was discarded as “burnin”. Maximum likelihood analysis wasperformed with PhyML 3.0, using LG substitution rate matrix, gammadistributed rate variation (8 categories) and was bootstrapped 1000times. A BioNJ distance-based phylogenetic analysis was performed withPAUP 4b10 (Swofford, D. L., Phylogenetic Analysis Using Parsimony (*andOther Methods), Version 4 (Sinauer Associates, Sunderland, Mass., 2003))and bootstrapped 1000 times. Ancestral sequence reconstruction wasperformed with PAML 4.2b (Yang, Z., Mol Biol Evol 24, 1586-1591 (2007))using the consensus Bayesian phylogenetic tree and mean alpha rateparameter. Branch lengths were fixed.

Fly Strains and Immunohistochemistry.

dTrpA1^(SH)-Gal4, UAS-dTRPA1, and UAS-dTRPA1^(dsRNA) transgenic strains(Hamada, et al., Nature 454, 217-220 (2008), as well as Dll-Gal4(Calleja, et al., Science 274, 252-255 (1996)), MJ94-Gal4 (Gendre, etal., Development 131, 83-92 (2004) and Joiner et al., J Neurosci 17,9384-9391 (1997)), Gr66a-Gal4 (Dunipace, et al., Curr Biol 11, 822-835(2001)), UAS-Painless^(AR9) (Al-Anzi, B., W. D. Tracey, Jr., and S.Benzer, Curr Biol 16, 1034-1040 (2006)), and painless (Tracey, et al.,Cell 113, 261-273 (2003)) mutants have been previously described.UAS-nls:GFP and UAS-mCD8: GFP fly strains were obtained fromBloomington. Anti-dTRPA1 immunohistochemistry was performed as describedin (Rosenzweig, et al., Genes Dev 19, 419-424 (2005)). Details of thecreation of dTrpA1^(fs) and dTrpA1^(ins) were previously reported anddescribed in Rosenzweig, M., K. Kang, and P. A. Garrity, Proc Nall AcadSci USA 105, 14668-14673 (2008) and Hamada, et al., Nature 454, 217-220(2008)). Briefly, dTrpA1^(fs) has a 2-bp insertion creating frameshiftmutation within the third ankyrin repeat of dTRPA1, prior to thetransmembrane regions. dTrpA1^(ins) contains two mutated copies ofdTrpA1 that flank vector targeting sequences: one copy lacks the ionpore and sixth transmembrane domain, while the other copy lacks thepromoter and upstream sequences, all of exon 1, part of exon 2, andcontains the 2 bp insertion mutation present in dTrpA1^(fs).

PER Behavioral Assays,

Two to seven day old flies were starved overnight on wet Kim wipes,anaesthetized on ice, and affixed to a glass slide. Flies recovered in ahumidified chamber for at least 2 hrs at room temperature prior totesting. During the PER assay, the fly was first satiated with water,then a solution containing tastants was touched to the forelegs as aliquid ball on a pipette tip. If the proboscis was extended and contactwith the food was maintained for 2-3 sec, the response was scored as 1.If the proboscis stuttered on the tastant, or contact was brief, a 0.5was awarded. If the proboscis failed to contact the solution within 5sec of offering, a 0 was awarded. Each fly was offered tastants fivetimes per experiment, and between offerings water was given tosatiation. Because AITC, cinnamaldehyde and NMM were usually accepted onfirst offering, PER frequency was calculated for the second throughfifth offerings (sum of four scores per fly divided by 4). Responses tosucrose resumed within ˜10 minutes after pungent chemical exposure,indicating that feeding was not permanently impaired (K.K. and P.G.,unpublished). For leg only PER assays, the procedures were as aboveexcept flies were not allowed to contact the food with their proboscis.The inventors found that NMM had no effect on ingestion when using apreviously published ingestion-independent PER assay for chemicalsensitivity (Al-Anzi, B., W. D. Tracey, Jr., and S. Benzer, Curr Biol16, 1034-1040 (2006)), suggesting the inhibitory effects of AITC in thatassay were not gustatory.

Two-Electrode Voltage Clamping on Xenopus laevis Oocytes.

Agonist-evoked dTRPA1 currents were recorded as previously described in(Hamada, et al., Nature 454, 217-220 (2008)), with the followingmodifications. Agonists of interest were added to the oocyte perfusionbuffer (96 mM NaCl, 1 mM MgCl2, 4 mM KCl, and 5 mM HEPES, pH 7.6).Voltage was initially held at −60 mV, and a 300-ms voltage ramp (−60 mVto 60 mV) per sec was applied to dTRPA1- or AgTRPA1-expressing oocytesduring perfusion of agonist-containing buffer. Typical oocyte restingmembrane potentials were between −25 and −60 mV. Agonist-elicitedcurrents were specific and TRPA1-dependent; they were absent fromuninjected or water-injected oocytes and were significantly reduced bymutation of two cysteine residues within dTRPA1 (FIGS. 3A-3E and 4A, anddata not shown). Furthermore, they were inhibited by ruthenium red,which partially inhibits warmth-activated dTRPA1 and agTRPA1 currents,and they exhibited the reversal potential and rectification propertiespreviously associated with warmth-activated dTRPA1 and agTRPA1 currents(Hamada, et al., Nature 454, 217-220 (2008)). EC50s for wild type dTRPA1channels were obtained at −60 mV, with AITC provided for 60 sec with 30sec intervals between increasing concentrations. The low sensitivity ofdTRPA1-2C to AITC precluded EC50 analysis of the mutant channel.

Larval Neuromuscular Junction Electrophysiology.

TRPA channels were expressed in larval motor neurons using OK371-GAL4, adriver specific for glutamatergic neurons, as described in Pulver, etal., J Neurophysiol 101, 3075-3088 (2009)). In all preparations, theventral ganglion was dissected away, leaving only motor axons andterminals. Larval muscle 6 (m6) was impaled with a sharp electrode(10-20 MΩ containing 3M KCl. Resting membrane potentials were typicallybetween −40 and −50 mV. Saline was perfused over the preparation, thenincreasing concentrations of cinnamaldehyde applied using a custom builtgravity perfusion system. EJP frequency was measured ˜30 sec afterapplication of each concentration using analysis scripts in Spike 2(Cambridge Electronic Design, Cambridge, UK). Painless was overexpressedusing the functional rescue construct UAS-Painless^(AR9) (Al-Anzi, B.,W. D. Tracey, Jr., and S. Benzer, Curr Biol 16, 1034-1040 (2006)).

Molecular Biology.

Substitutions of cysteine/lysine residues in dTrpA1 were made byswapping a region of wild type cDNA sequence including codons ofcysteine or lysine with mutated cassettes. A pair of mutuallycomplementary oligonucleotide primers with a desired mutation wereprepared, and each of them was paired with upstream or downstreamprimers for the first two PCR reactions. The resulting two PCR fragmentsoverlap in the mutant primer-annealing region that contains the replacedcodons, and served as template for the second PCR reaction amplifiedonly with the upstream and down stream primers. The upstream and downstream primers were designed to be just outside of specific restrictionendonuclease target sites that were used to clone the second PCRproducts back in the wild type dTrpA1 cDNA background sequence. Thefragments amplified by PCR were confirmed by sequencing after cloning tomake sure that only desired mutations were introduced in the final cDNAconstructs.

Sequence Alignment and Phylogeny.

Multiple sequence alignments were visualized using JAL2.4 (Waterhouse,et al., Bioinformatics 25, 1189-1191 (2009)). Conservation reflectsconservation of physico-chemical properties of residues was calculatedas described in (Livingstone, C. D. and G. J. Barton, CABIOS 9, 745-756(1993)). Quality is inversely proportional to the cost of mutations in aresidue, measure of likelihood of observing mutations (Waterhouse, etal., Bioinformatics 25, 1189-1191 (2009)). Consensus reflects percentageof modal residue. FIGS. 4A and 13 provide alternative alignments forPainless in C450 and C650 regions; neither indicates cysteineconservation. The LG substitution matrix was as described in Le, S. Q.and O. Gascuel, Mol Biol Evol 25, 1307-1320 (2008). The input data forthe ancestral reconstruction was the consensus Bayesian phylogenetictree depicted in FIG. 4D. The inventors used the “marginalreconstruction” method (RateAncestor=1) in PAML4 (Nakagawa, T. and L. B.Vosshall, Curr Opin Neurobiol 19, 284-292 (2009)), which determines theposterior probability of each amino acid at each site in the proteinalignment for a given node. The alpha parameter (for gamma distributedrate variation across sites) was fixed to the Bayesian expected value asdetermined by MrBayes.

Results and Discussion

Chemical nociception, the detection of tissue-damaging chemicals, isimportant for animal survival and causes human pain and inflammation,but its evolutionary origins are largely unknown. Reactive electrophilesare a class of noxious compounds humans find pungent and irritating,like allyl isothiocyanate (in wasabi) and acrolein (in cigarette smoke).See for example, Basbaum, et al., Cell 139, 267-284 (2009); Bessac, B.F. and S. E. Jordt, Physiology (Bethesda) 23, 360-370 (2008); andEisner, T., in Chemical Ecology, edited by E. Sondheimer and J. B.Simeone (New York, 1970), Vol. Academic Press. Insects to humans findreactive electrophiles aversive (Basbaum, et al., Cell 139, 267-284(2009); Bessac, B. F. and S. E. Jordt, Physiology (Bethesda) 23, 360-370(2008); and Eisner, T., in Chemical Ecology, edited by E. Sondheimer andJ. B. Simeone (New York, 1970), Vol. Academic Press), but whether thisreflects conservation of an ancient sensory modality has been unclear.Here the inventors have identify the molecular basis of reactiveelectrophile detection in flies. The inventors demonstrate that dTRPA1,the Drosophila melanogaster ortholog of the human irritant sensor, actsin gustatory chemosensors to inhibit reactive electrophile ingestion.The inventors further demonstrate that fly and mosquito TRPA1 orthologsare molecular sensors of electrophiles, using a mechanism conserved withvertebrate TRPA1s. Phylogenetic analyses indicate invertebrate andvertebrate TRPA1s share a common ancestor that possessed criticalcharacteristics required for electrophile detection. These findingssupport emergence of TRPA1-based electrophile detection in a commonbilaterian ancestor, with widespread conservation throughout vertebrateand invertebrate evolution. Such conservation contrasts with theevolutionary divergence of canonical olfactory and gustatory receptorsand can relate to electrophile toxicity.

Reactive electrophiles are tissue-damaging agents that modify nucleicacids, proteins and other biomolecules. Reactive electrophiles areaversive to both vertebrates and invertebrates (Basbaum, et al., Cell139, 267-284 (2009); Bessac, B. F. and S. E. Jordt, Physiology(Bethesda) 23, 360-370 (2008); and Eisner, T., in Chemical Ecology,edited by E. Sondheimer and J. B. Simeone (New York, 1970), Vol.Academic Press); plants and animals use them as deterrents (Eisner, T.,in Chemical Ecology, edited by E. Sondheimer and J. B. Simeone (NewYork, 1970), Vol. Academic Press). Despite their importance as naturalrepellents, the cellular and molecular mechanisms by which reactiveelectrophiles deter insects have not been established. We examinedDrosophila responses to reactive electrophiles using feeding. When adroplet of food (350 mM sucrose) contacts the legs of a hungry fly, thefly extends its proboscis to drink. This proboscis extension response(PER) is robust and sustained; >90% of the second through fifthofferings of food elicited PER (FIG. 1B). Adding the reactiveelectrophile allyl isothiocyanate (AITC, FIG. 1A) to the fooddramatically inhibited this response (FIG. 1B). This effect wasgeneralized to other reactive electrophiles using N-methyl maleimide(NMM) and cinnamaldehyde (CA) (FIG. 1A). Both NMM and CA robustlyinhibited feeding (FIG. 1B). This inhibitory effect appeared gustatory,not olfactory, because NMM is non-volatile (m.p. 93° C.) and avoidancerequired ingestion. When only leg contact with food was permitted,reactive electrophiles did not affect PER (FIG. 1C), suggesting thatchemosensors along the path of food intake rather than the legs mediatetheir inhibitory effects. The bitter compound caffeine, for which thereare tarsal receptors (Thorne, et al., Curr Biol 14, 1065-1079 (2004) andWang, et al., Cell 117, 981-991 (2004)), robustly inhibited PER evenwhen ingestion was not permitted (FIG. 1C).

In vertebrates, the cation channel TRPA1 is a molecular receptor forreactive electrophiles, forming covalent adducts with these chemicalsand activating sensory neurons to mediate irritation and pain. See forexample, Bandell, et al., Neuron 41, 849-857 (2004); Jordt, et al.,Nature 427, 260-265 (2004); Bautista, et al., Cell 124, 1269-1282(2006); Kwan, et al., Neuron 50, 277-289 (2006); Hinman, et al., ProcNatl Acad Sci USA 103, 19564-19568 (2006); and Macpherson, et al.,Nature 445, 541-545 (2007). Previous in vitro physiological analysessuggested that Drosophila TRPA1 relatives dTRPA1 and Painless were notactivated by electrophiles (Bandell, et al., Neuron 41, 849-857 (2004)and Sokabe, et al., J Neurosci 28, 9929-9938 (2008)), raising thepossibility that flies might use different mechanisms to detect thesechemicals. We reexamined the possible involvement of dTRPA1 and Painlessin vivo, assessing the gustatory response to reactive electrophiles. Incontrast to wild type, dTrpA1 loss-of-function mutants showed noreduction in PER when offered food containing AITC, NMM, or CA (FIG.1B). Similar defects were observed using two loss-of-function dTrpA1alleles (dTrpA1^(ins) and dTrpA1^(fs)) (Rosenzweig, M., K. Kang, and P.A. Garrity, Proc Natl Acad Sci USA 105, 14668-14673 (2008)) and dTrpA1cDNA expression rescued this defect (FIG. 1D). Thus this response toreactive electrophiles is entirely TRPA1-dependent. dTrpA1 mutantsresponded to other deterrents, as caffeine inhibited PER (FIG. 1B). Incontrast, painless mutants remained responsive to reactive electrophiles(FIG. 5), although responses were less robust than controls, suggestinga possible auxiliary function consistent with previous report (Al-Anzi,B., W. D. Tracey, Jr., and S. Benzer, Curr Biol 16, 1034-1040 (2006)).

dTRPA1 protein expression was detected in the mouthparts (data notshown), but not legs or labellum. Within the mouthparts, dTRPA1 wasexpressed in neurons innervating sensilla #8 and #9 of the labral senseorgan (LSO) (data not shown). LSO sensilla contain pores that open ontothe esophagus lumen, providing access to chemicals in ingested food.Thus, dTRPA1 is expressed in an appropriate place to mediateingestion-dependent responses.

To test the significance of peripheral dTRPA1 expression,tissue-specific RNAi was performed using three promoters whoseexpression overlaps dTRPA1-positive LSO neurons: Dll-Gal4, expressedbroadly within peripheral tissue, MJ94-Gal4, expressed in chemoreceptorsand the brain (Gendre, et al., Development 131, 83-92 (2004)), andGr66a-Gal4, expressed in chemoreceptors implicated in aversive responses(Thorne, et al., Curr Biol 14, 1065-1079 (2004) and Wang, et al., Cell117, 981-991 (2004)) (data not shown). dTRPA1 knockdown using eachpromoter robustly reduced NMM's effect on PER, consistent with arequirement for dTRPA1 in peripheral chemoreceptors (FIG. 2A). Incontrast, dTRPA1 knockdown in the AC thermosensory neurons of the headusing dTrpA1^(SH)-Gal4 (Hamada, et al., Nature 454, 217-220 (2008)) hadno effect (FIG. 2A). These data cleanly distinguish the sites of actionfor dTRPA1 in thermotaxis and gustation, with the former involving ACneurons (Hamada, et al., Nature 454, 217-220 (2008)) and the latterperipheral sensory neurons.

dTRPA1 expression in peripheral chemosensors also sufficed to inducereactive electrophile-dependent PER inhibition. dTRPA1 cDNA expressionwith Dll-Gal4, MJ94-Gal4, or Gr66a-Gal4 rescued the mutant phenotype(FIG. 2B). In addition, ectopic expression of dTRPA1 in legchemoreceptors (using Gr66a-Gal4) allowed flies to respond toelectrophiles via leg contact (FIG. 2C). Thus, dTRPA1 expression inperipheral chemosensory neurons is both necessary and sufficient forreactive electrophile-induced feeding inhibition.

dTRPA1 has been considered unresponsive to electrophiles (Bandell, M. etal., Neuron 41, 849-857 (2004) and Xiao, B., et al., J Neurosci 28,9640-9651 (2008)); however, the inventors recently found that theoriginal dTRPA1 cDNA contained a partially inactivating mutation(Hamada, et al., Nature 454, 217-220 (2008)). Using wild-type dTRPA1,the inventors discovered dTRPA1 was activated by multiple reactiveelectrophiles when expressed in Xenopus oocytes (FIGS. 3A-3D, 6 and 7).dTRPA1 orthologs from two other Drosophila species, D. mojavensis and D.virilis, and the malaria mosquito Anopheles gambiae also responded tothese chemicals (FIGS. 3E and 6). Combined with the sensitivity ofmosquito TRPA1 to AITC in HEK cells, as described in Xiao, B., et al., JNeurosci 28, 9640-9651 (2008), these findings demonstrate multipleinsect TRPA1s respond to electrophiles. Notably, electrophile-activatedcurrents persisted after chemical withdrawal (FIGS. 3A-3F), contrastingwith the transient activation of dTRPA1 by warmth (Hamada, et al.,Nature 454, 217-220 (2008)). Persistent activation by electrophiles hasbeen observed for mammalian TRPA1s, and it is thought to reflectcovalent association between agonists and channel. See, for example,Hinman, A., et al., Proc Natl Acad Sci USA 103, 19564-19568 (2006) andMacpherson, L. J., et al., Nature 445, 541-545 (2007). This similaritysuggested reactive electrophiles might activate insect and mammalianTRPA1s via similar mechanisms. Finally, we demonstrated that ectopicexpression of dTRPA1 in fly neurons can confer physiological sensitivityto electrophiles. In contrast to controls or motorneurons expressingPainless, dTRPA1-expressing motorneurons were cinnamaldehyde-responsive(FIGS. 3F and 8). Thus, dTRPA1 acts as an electrophile sensor inmultiple contexts.

Reactive electrophiles activate mammalian TRPA1s by forming covalentbonds with cysteine and lysine residues in the channel; six residues(five cysteines and one lysine) are implicated in electrophile detectionand mutations in these residues decrease electrophile sensitivity. See,for example, Hinman, A., et al., Proc Natl Acad Sci USA 103, 19564-19568(2006) and Macpherson, L. J., et al., Nature 445, 541-545 (2007). InsectTRPA1s conserve five of these six residues (data not shown). MutatingdTRPA1 cysteines 650 and 670 to serines (dTRPA1-2C) significantlydecreased AITC sensitivity (FIGS. 4A and 4B); this dTRPA1-2C mutantremained robustly warmth-activated (FIG. 9). The shared requirement forthese residues further supports a common mechanism for reactiveelectrophile sensing by fly and vertebrate TRPA1s. TRPA1s also exhibitsome species-specific differences in chemical sensitivity;2-aminoethoxydiphenyl borate (2-APB) and nicotine, conservedcysteine-independent agonists of mammalian TRPA1s (Hinman, A., et al.,Proc Natl Acad Sci USA 103, 19564-19568 (2006) and Talavera, K. et al.,Nicotine activates the chemosensory cation channel TRPA1. Nat Neurosci12, 1293-1299 (2009)), did not activate dTRPA1 (FIG. 10).

While functional similarities between insect and vertebrate TRPA1s couldreflect conservation of an ancestral mechanism for electrophiledetection, the electrophile insensitivity of invertebrate TRPA1relatives like Painless (Sokabe, T., et al., J Neurosci 28, 9929-9938(2008)) and C. elegans TRPA1 (ceTRPA1) (Kindt, K. S., et al., NatNeurosci 10, 568-577 (2007)) raised the possibility that some insect andvertebrate TRPA1s recently converged on similar mechanisms. To testthese alternatives, a phylogeny of TRPA proteins was constructed usingthree different approaches, Bayesian inference (Ronquist, F. and J. P.Huelsenbeck, Bioinformatics 19, 1572-1574 (2003)), maximum likelihood(Guindon, S., et al., Methods Mol Biol 537, 113-137 (2009)), andneighbor joining (Saitou, N. and M. Nei, Mol Biol Evol 4, 406-425(1987)).

Trees were rooted using TRPAs from the unicellular choanoflagellate M.brevicollis. All methods indicated with high confidence that theelectrophile-activated TRPA1 channels of invertebrates and vertebratesbelong to a monophyletic Glade, the TRPA1 Glade, distinct from otherTRPAs (termed basal TRPAs) by both tree topology and branch lengths(data not shown). The TRPA1 Glade channels derive from a commonancestral TRPA1 present in the common ancestor of vertebrates andinvertebrates (data not shown). Consistent with a common evolutionaryorigin of electrophile detection, sequence reconstruction (Yang, Z., MolBiol Evol 24, 1586-1591 (2007)) suggested this ancestral TRPA1 containedall six critical residues associated with electrophile sensing. PAMLresidue identity estimates for ancestral TRPA1 were calculated to be99.9% for cysteine at position 445, 79% for cysteine at position 452,99.8% for cysteine at position 650, 100% for cysteine at position 670,98.9% for cysteine at position 694, and 100% for lysine at position 744.This mode of electrophile detection appears specific to TRPA1 Glademembers, as no known basal TRPAs conserve more than one of the fivecysteines implicated in electrophile detection (data not shown).

These analyses also suggest revisions to proposed relationships amongTRPAs. Painless has been called the fly homolog of mammalian TRPA1, andceTRPA1 considered the nematode TRPA1 ortholog. However, all analysesindicated that neither Painless nor ceTRPA1 descend from the ancestralTRPA1; both are closer to anemone and choannoflagellate TRPAs (data notshown). Consistent with their electrophile insensitivity (Sokabe, T., etal., J Neurosci 28, 9929-9938 (2008) and Kindt, K. S., et al., NatNeurosci 10, 568-577 (2007)), Painless and ceTRPA1 lack most cysteinesimplicated in electrophile detection (data not shown). During evolution,nematodes appear to have lost their TRPA1 ortholog and vertebrates theirbasal TRPA(s) (data not shown).

Functional conservation of TRPA1 provides a simple molecular foundationfor the widespread aversion to reactive electrophiles across the animalkingdom. The conservation of reactive electrophile detection differsfrom other chemical senses like olfaction and gustation whose originsare molecularly diverse and evolutionarily distinct. See for example,Bargmann, C. I., Nature 444, 295-301 (2006) and Nakagawa, T. and L. B.Vosshall, Curr Opin Neurobiol 19, 284-292 (2009). For example, many flyolfactory receptors are ion channels rather than the G-protein coupledreceptors of vertebrates. See Nakagawa, T. and L. B. Vosshall, Curr OpinNeurobiol 19, 284-292 (2009). Reactive electrophile detection alsocontrasts with capsaicin detection; capsaicin activates mammaliannociceptors (Basbaum, A. I., et al., Cell 139, 267-284 (2009)), butelicits no acute response in flies or nematodes. The exceptionalconservation of TRPA1-mediated nociception could relate to the toxicityof reactive electrophiles (Gomes R, Meek M E, and Eggleton M, ConciseInternational Chemical Assessment Document No 43. (World HealthOrganization, Geneva, (2002)), which could provide selective pressurefor maintaining an effective monitoring system.

dTRPA1's ability to mediate aversive responses to natural deterrentssuggests insect TRPA1s as targets for developing new deterrents. InsectTRPA1 agonists can be useful against an array of pests, as diseasevectors from mosquitoes to lice and agricultural pests from flourbeetles to aphids (Hamada, F. N., et al., Nature 454, 217-220 (2008))contain dTRPA1 relatives. The invention provides methods of identifyinginsect specific TRPA1 modulators. Such selective insect TRPA1 modulatorscan maximize pest deterrence while minimizing irritation to otheranimals.

All patents and other publications identified in the specification andexamples are expressly incorporated herein by reference for allpurposes. These publications are provided solely for their disclosureprior to the filing date of the present application. Nothing in thisregard should be construed as an admission that the inventors are notentitled to antedate such disclosure by virtue of prior invention or forany other reason. All statements as to the date or representation as tothe contents of these documents is based on the information available tothe applicants and does not constitute any admission as to thecorrectness of the dates or contents of these documents.

What is claimed:
 1. A method of identifying an insect-specific transientreceptor potential ion channel A1 (TRPA1) modulator comprising: (a)contacting a test compound with an insect TRPA1 and a vertebrate TRPA1,wherein the test compound is a reactive electrophile; and (b) assayingmodulation of insect and vertebrate TRPA1 activity, wherein ifmodulation of the activity of insect TRPA1 is increased by at least 10%relative to modulation of activity of the vertebrate TRPA, the testcompound is identified as an insect-specific TRPA1 modulator.
 2. Themethod of claim 1, wherein the compound inhibits the activity of theinsect TRPA1.
 3. The method of claim 1, wherein the compound activatesthe insect TRPA1.
 4. The method of claim 1, wherein the insect TRPA1 isselected from the group consisting of D. melanogaster TRPA1 isoform F(Accession No. ABW08500.3) (SEQ ID NO: 1), D. melanogaster TRPA1 isoformE (Accession No. AAF50356.4) (SEQ ID NO: 2), D. melanogaster TRPA1isoform F (Accession No. NP_001097554.3) (SEQ ID NO: 3), D. melanogasterTRPA1 isoform E (Accession No. NP_648263.4) (SEQ ID NO: 4), D.melanogaster TRPA1 (Accession No. Q7Z020.3) (SEQ ID NO: 5), Anophelesgambiae TRPA1 (Accession No. ACC86138.1) (SEQ ID NO: 6), and Triboliumcastaneum hypothetical protein TcasGA2_TC002449 (Accession No.EFA01253.1) (SEQ ID NO: 7).
 5. The method of claim 1, wherein thevertebrate TRPA1 is selected from the group consisting of Rattusnorvegicus transient receptor potential cation channel, subfamily A,member 1 (Accession No. NP_997491.1) (SEQ ID NO: 8); Rattus norvegicustransient receptor potential cation channel subfamily A member 1(Accession No. AAS78661.1) (SEQ ID NO: 9); Mus musculus transientreceptor potential cation channel, subfamily A, member 1 (Accession No.NP_808449.1) (SEQ ID NO: 10); Homo sapiens transient receptor potentialcation channel subfamily A member 1 (Accession No. NP_015628.2) (SEQ IDNO: 11); Mus musculus transient receptor potential cation channel,subfamily A, member 1 (Accession No. AAI31964.1) (SEQ ID NO: 12); Musmusculus transient receptor potential cation channel, subfamily A,member 1 (Accession No. AAI20564.1) (SEQ ID NO: 13); Mus musculustransient receptor potential cation channel, subfamily A, member 1,isoform CRA_b (Accession No. EDL14332.1) (SEQ ID NO: 14); Mus musculustransient receptor potential cation channel, subfamily A, member 1,isoform CRA_a (Accession No. EDL14331.1) (SEQ ID NO: 15); Bos Taurustransformation sensitive protein p120 (Accession No. XP_581588.2) (SEQID NO: 16); Pan troglodytes predicted ankyrin-like protein 1 (AccessionNo. XP_519806.2) (SEQ ID NO: 17); Macaca mulatta predicted ankyrin-likeprotein 1 (Accession No. XP_001083172.1) (SEQ ID NO: 18); Gallus galluspredicted similar to transient receptor potential cation channelsubfamily A member 1 (Accession No. XP_418294.2) (SEQ ID NO: 19); Daniorerio TRPA1 (Accession No. AAV37177.1) (SEQ ID NO: 20); and Danio reriotransient receptor potential cation channel, subfamily A, member 1a(Accession No. NP_001007066.1) (SEQ ID NO: 21).
 6. The method claim 1,wherein the insect TRPA1 or the vertebrate TRPA1 is inside a cell. 7.The method of claim 6, wherein the cell is an oocyte.
 8. The method ofclaim 1, wherein the test compound is extracted from a bacteria, plant,fungi, animal cell, or animal tissue.